var docs;if (!docs) docs =[]; docs["36"]={"3601":"<p><b>Title</b> LamoTRIgine / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effects of lamotrigine in patients in whom a hormonal contraceptive is added/dose increased. An increased dosage of lamotrigine may be needed. Similarly, monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased; a reduced dosage of lamotrigine may be needed.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Plasma lamotrigine concentrations were an average of 49% lower in 7 patients following the addition of an oral contraceptive.<sup>1</sup> Most of the patients experienced increased seizure frequency when the contraceptive was added and/or adverse effects from lamotrigine following contraceptive discontinuation. Similarly, the lamotrigine AUC was an average of 52% lower with concurrent ethinyl estradiol and levonorgestrel in 16 subjects.<sup>2</sup> Similar changes in the dose-adjusted lamotrigine concentration with estrogen-containing contraceptives has been reported in several other studies.<sup>3,4,5,6</sup><br><br>Increases in lamotrigine clearance and evidence of increased formation of the lamotrigine N-2-glucuronide suggest that the most likely mechanism for this interaction is enhanced lamotrigine glucuronidation (possibly via UGT1A4).<sup>4,5,6</sup><br><br>Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. <i>Epilepsy Res</i>. 2001;47(1-2):151-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11673029\">[PubMed 11673029]</a></p>\n<p>2. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. <i>Br J Clin Pharmacol</i>. 2006;61(2):191-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16433873\">[PubMed 16433873]</a></p>\n<p>3. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. <i>Epilepsia</i>. 2005;46(9):1414-1417. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16146436\">[PubMed 16146436]</a></p>\n<p>4. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. <i>Seizure</i>. 2008;17(2):199-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18201913\">[PubMed 18201913]</a></p>\n<p>5. Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. <i>Neurology</i>. 2009;73(17):1388-1393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19858461\">[PubMed 19858461]</a></p>\n<p>6. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. <i>Epilepsia</i>. 2007;48(3):484-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346247\">[PubMed 17346247]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3602":"<p><b>Title</b> Vitamin K Antagonists / Mercaptopurine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mercaptopurine may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of coumarin derivatives if mercaptopurine is initiated/dose increased, or increased effects if mercaptopurine is discontinued/dose decreased. An adjustment in warfarin dosage may be needed with the start and completion of each mercaptopurine therapy cycle.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A few case reports describe an increased requirement in warfarin or acenocoumarol dosage when patients were concurrently treated with azathioprine or mercaptopurine.<sup>1,2,3,4,5</sup> In one case warfarin requirements decreased to 5 mg/day within a few weeks of discontinuing azathioprine (14-17 mg/day while taking azathioprine).<sup>1</sup> Another case describes increased warfarin requirements during each cycle of mercaptopurine therapy.<sup>4</sup> The mechanism of these interactions is unknown. An animal study has demonstrated the potential for mercaptopurine to increase the synthesis or activation of prothrombin, thereby increasing coagulability in the absence of warfarin.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Singleton JD and Conyers L, “Warfarin and Azathioprine: An Important Drug Interaction,” <i>Am J Med</i>, 1992, 92(2):217-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1543209\">[PubMed 1543209]</a></p>\n<p>2. Rivier G, Khamashta MA, and Hughes GR, “Warfarin and Azathioprine: A Drug Interaction Does Exist,” <i>Amer J Med</i>, 1993, 95(3):342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8368235\">[PubMed 8368235]</a></p>\n<p>3. Spiers AS and Mibashan RS, “Letter: Increased Warfarin Requirement During Mercaptopurine Therapy: A New Drug Interaction,” <i>Lancet</i>, 1974, 2(7874):221-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135641\">[PubMed 4135641]</a></p>\n<p>4. Martin LA and Mehta SD, “Diminished Anticoagulant Effects of Warfarin with Concomitant Mercaptopurine Therapy,” <i>Pharmacotherapy</i>, 2003, 23(2):260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12587816\">[PubMed 12587816]</a></p>\n<p>5. Fernandez MA, Regadera A, and Aznar J, “Acenocoumarol and 6-mercaptopurine: An Important Drug Interaction,” <i>Haematologica</i>, 1999, 84(7):664-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10406922\">[PubMed 10406922]</a></p>\n<p>6. Martini A and Jahnchen E, “Studies in Rats on the Mechanism By Which 6-Mercaptopurine Inhibits the Anticoagulant Effect of Warfarin,” <i>J Pharmacol Exp Ther</i>, 1977, 201(3):547-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=864594\">[PubMed 864594]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3604":"<p><b>Title</b> Vitamin K Antagonists / Ifosfamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ifosfamide may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased INR/effects of coumarin derivatives when ifosfamide is initiated/dose increased, and decreased INR/effects when ifosfamide is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One report describes three warfarin-stable patients who experienced a marked increase in INR when treated with ifosfamide/mesna.<sup>1</sup> Ifosfamide is reported to inhibit, to some degree, CYP3A4 enzymes.<sup>2,3</sup> Warfarin is partially, though not primarily, metabolized by these enzymes. Ifosfamide does not appear to inhibit CYP2C, the enzymes most responsible for warfarin metabolism.<sup>3</sup> A complete understanding of the mechanism of this apparent interaction is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hall G, Lind MJ, Huang M, et al, “Intravenous Infusions of Ifosfamide/Mesna and Perturbation of Warfarin Anticoagulant Control,” <i>Postgrad Med J</i>, 1990, 66(780):860-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2129174\">[PubMed 2129174]</a></p>\n<p>2. Baumhakel M, Kasel D, Rao-Schymanski RA, et al, “Screening for Inhibitory Effects of Antineoplastic Agents on CYP3A4 in Human Liver Microsomes,” <i>Int J Clin Pharmacol Ther</i>, 2001, 39(12):517-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11770832\">[PubMed 11770832]</a></p>\n<p>3. Murray M, Butler AM, and Stupans I, “Competitive Inhibition of Human Liver Microsomal Cytrochrome P450 3A-Dependent Steroid 6 Beta-hydroxylation Activity by Cyclophosphamide and Ifosfamide <i>in vitro</i>,” <i>J Pharmacol Exp Ther</i>, 1994, 270(2):645-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8071856\">[PubMed 8071856]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3605":"<p><b>Title</b> Vitamin K Antagonists / Etoposide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Etoposide may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased INR/warfarin effects if etoposide is initiated.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe increased anticoagulation in warfarin-stable patients following the addition of etoposide-containing regimens.<sup>1,2</sup> In one case a patient's INR increased approximately sixfold within 16 days of starting etoposide and carboplatin.<sup>1</sup> In another case a patient's PT increased 8-15 seconds after receiving etoposide and vindesine.<sup>2</sup> This second case occurred again upon rechallenge. The mechanism of this apparent interaction is unclear. Etoposide has been reported to inhibit CYP2C8 and 3A4 isoenzymes. Inhibiting either isoenzyme could result in decreased warfarin clearance, and increased effects. Acenocoumarol is not affected by these enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Le AT, Hasson NK, and Lum BL, “Enhancement of Warfarin Response in a Patient Receiving Etoposide and Carboplatin Chemotherapy,” <i>Ann Pharmacother</i>, 1997, 31:1006-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9296241\">[PubMed 9296241]</a></p>\n<p>2. Ward K and Bitran JD, “Warfarin, Etoposide and Vindesine Interactions,” <i>Cancer Treat Rep</i>, 1984, 68:817-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6539172\">[PubMed 6539172]</a></p>\n<p>3. Desai PB, Duan JZ, Zhu YW, et al, “Human Liver Microsomal Metabolism of Paclitaxel and Drug Interactions,” <i>Eur J Drug Metab Pharmacokinet</i>, 1998, 23(3):417-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9842986\">[PubMed 9842986]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3608":"<p><b>Title</b> Clopidogrel / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> AtorvaSTATin may diminish the antiplatelet effect of Clopidogrel. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Clopidogrel-related platelet inhibition was reduced by concurrent atorvastatin treatment in a dose-dependent manner (% platelet aggregation = 34%, 58%, 74%, and 89% with atorvastatin doses of zero, 10mg, 20mg, and 40mg, respectively) in a study of 44 patients undergoing stent placement who were receiving clopidogrel alone or with either atorvastatin or pravastatin.<sup>1</sup> A study of 47 patients treated with clopidogrel also found evidence that pre-treatment with either atorvastatin or simvastatin significantly impaired the antiplatelet response to clopidogrel (assessed via p-selectin expression), with a greater impact on the response following the clopidogrel loading dose (300mg x1) than during the maintenance (75mg daily) phase (29.3% relative decrease in response vs. 16.6% relative decrease).<sup>2</sup> Treatment with a CYP3A4-metabolized statin (atorvastatin or simvastatin) was also associated with a greater evidence of myocardial damage (positive troponin in 41.6% vs. 8% of patients) following percutaneous coronary intervention (PCI) than treatment with a non-CYP3A4-metabolized statin (pravastatin or fluvastatin) in a study of 211 consecutive patients.<sup>3</sup> Use of atorvastatin, use of any other CYP3A4 substrate, and delayed filling of the clopidogrel prescription were the only significant variables associated with an increased risk of negative outcomes in a cohort study of 2,927 PCI patients receiving clopidogrel.<sup>4</sup> An in vitro study similarly found that atorvastatin lactone was a potent inhibitor of clopidogrel activation.<sup>5</sup><br><br>Somewhat at odds with these studies, a study of platelet response to clopidogrel in a group of 21 healthy volunteers found that concurrent administration of simvastatin or fluvastatin was associated with impaired clopidogrel response; however, concurrent rosuvastatin, pravastatin, or atorvastatin did not interfere with clopidogrel response.<sup>6</sup><br><br>In contrast to these studies, numerous clinical studies (including both secondary/post hoc analyses of larger studies and prospective studies designed to address this particular question) have found that neither atorvastatin nor other CYP3A4-metabolized statins significantly impair the antiplatelet effects of clopidogrel.<sup>7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23</sup><br><br>The proposed mechanism for this potential interaction was inhibition of clopidogrel metabolism via CYP3A4 to its active metabolite by the CYP3A4 substrate atorvastatin or other statins that were CYP3A4 substrates (principally simvastatin and lovastatin).<sup>1,5</sup> Data from one study showed that the CYP3A4 inhibitors erythromycin and troleandomycin were able to significantly interfere with clopidogrel's antiplatelet effects and that the CYP3A-inducer rifampin was able to increase the antiplatelet effect of clopidogrel.<sup>1</sup> However, considering the total body of evidence available concerning this possible interaction, the majority of the available data suggests any interaction is unlikely or of limited significance in most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lau WC, Waskell LA, Watkins PB, et al, “Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction,” <i>Circulation</i>, 2003, 107(1):32-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12515739\">[PubMed 12515739]</a></p>\n<p>2. Neubauer H, Gunesdogan B, Hanefeld C, et al, “Lipophilic Statins Interfere with the Inhibitory Effects of Clopidogrel on Platelet Function--a Flow Cytometry Study,” <i>Eur Heart J</i>, 2003, 24:1744-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14522569\">[PubMed 14522569]</a></p>\n<p>3. Gulec S, Ozdol C, Rahimov U, et al, “Myonecrosis after Elective Percutaneous Coronary Intervention: Effect of Clopidogrel-Statin Interaction,” <i>J Invasive Cardiol</i>, 2005, 17:589-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16264203\">[PubMed 16264203]</a></p>\n<p>4. Brophy JM, Babapulle MN, Costa V, et al, “A Pharmacoepidemiology Study of the Interaction between Atorvastatin and Clopidogrel after Percutaneous Coronary Intervention,” <i>Am Heart J</i>, 2006, 152:263-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16875906\">[PubMed 16875906]</a></p>\n<p>5. Clarke TA and Waskell LA, “The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin,” <i>Drug Metab Dispos</i>, 2003, 31(1):53-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12485953\">[PubMed 12485953]</a></p>\n<p>6. Mach F, Senouf D, Fontana P, et al, “Not All Statins Interfere with Clopidogrel During Antiplatelet Therapy,” <i>Eur J Clin Invest</i>, 2005, 35:476-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16101667\">[PubMed 16101667]</a></p>\n<p>7. Wienbergen H, Gitt AK, Schiele R, et al, “Comparison of Clinical Benefits of Clopidogrel Therapy in Patients with Acute Coronary Syndromes Taking Atorvastatin Versus Other Statin Therapies,” <i>Am J Cardiol</i>, 2003, 92:285-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12888133\">[PubMed 12888133]</a></p>\n<p>8. Saw J, Steinhubl SR, Berger PB, et al, “Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction from Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial,” <i>Circulation</i>, 2003, 108:921-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925453\">[PubMed 12925453]</a></p>\n<p>9. Muller I, Besta F, Schulz C, et al, “Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel,” <i>Circulation</i>, 2003, 108:2195-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14568892\">[PubMed 14568892]</a></p>\n<p>10. Mobley JE, Bresee SJ, Wortham DC, et al, “Frequency of Nonresponse Antiplatelet Activity of Clopidogrel During Pretreatment for Cardiac Catheterization,” <i>Am J Cardiol</i>, 2004, 93:456-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14969622\">[PubMed 14969622]</a></p>\n<p>11. Mitsios JV, Papathanasiou AI, Rodis FI, et al, “Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients with Acute Coronary Syndromes,” <i>Circulation</i>, 2004, 109:1335-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15023882\">[PubMed 15023882]</a></p>\n<p>12. Piorkowski M, Weikert U, Schwimmbeck PL, et al, “ADP Induced Platelet Degranulation in Healthy Individuals Is Reduced by Clopidogrel after Pretreatment with Atorvastatin,” <i>Thromb Haemost</i>, 2004, 92:614-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15351859\">[PubMed 15351859]</a></p>\n<p>13. Serebruany VL, Midei MG, Malinin AI, et al, “Absence of Interaction between Atorvastatin or Other Statins and Clopidogrel: Results from the Interaction Study,” <i>Arch Intern Med</i>, 2004, 164:2051-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15477442\">[PubMed 15477442]</a></p>\n<p>14. Gorchakova O, von Beckerath N, Gawaz M, et al, “Antiplatelet Effects of a 600 mg Loading Dose of Clopidogrel Are Not Attenuated in Patients Receiving Atorvastatin or Simvastatin for at Least 4 Weeks Prior to Coronary Artery Stenting,” <i>Eur Heart J</i>, 2004, 25:1898-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15522468\">[PubMed 15522468]</a></p>\n<p>15. Smith SM, Judge HM, Peters G, et al, “Multiple Antiplatelet Effects of Clopidogrel Are Not Modulated by Statin Type in Patients Undergoing Percutaneous Coronary Intervention,” <i>Platelets</i>, 2004, 15:465-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15763887\">[PubMed 15763887]</a></p>\n<p>16. Mitsios JV, Papathanasiou AI, Elisaf M, et al, “The Inhibitory Potency of Clopidogrel on ADP-Induced Platelet Activation Is Not Attenuated When It Is Co-Administered with Atorvastatin (20 mg/day) for 5 Weeks in Patients with Acute Coronary Syndromes,” <i>Platelets</i>, 2005, 16:287-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16011979\">[PubMed 16011979]</a></p>\n<p>17. Vinholt P, Poulsen TS, Korsholm L, et al, “The Antiplatelet Effect of Clopidogrel Is Not Attenuated by Statin Treatment in Stable Patients with Ischemic Heart Disease,” <i>Thromb Haemost</i>, 2005, 94:438-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16113837\">[PubMed 16113837]</a></p>\n<p>18. Wenaweser P, Windecker S, Billinger M, et al, “Effect of Atorvastatin and Pravastatin on Platelet Inhibition by Aspirin and Clopidogrel Treatment in Patients with Coronary Stent Thrombosis,” <i>Am J Cardiol</i>, 2007, 99:353-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17261397\">[PubMed 17261397]</a></p>\n<p>19. Saw J, Brennan DM, Steinhubl SR, et al, “Lack of Evidence of a Clopidogrel-Statin Interaction in the CHARISMA Trial,” <i>J Am Coll Cardiol</i>, 2007, 50:291-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17659194\">[PubMed 17659194]</a></p>\n<p>20. Trenk D, Hochholzer W, Frundi D, et al, “Impact of Cytochrome P450 3A4-Metabolized Statins on the Antiplatelet Effect of a 600-mg Loading Dose Clopidogrel and on Clinical Outcome in Patients Undergoing Elective Coronary Stent Placement,” <i>Thromb Haemost</i>, 2008, 99:174-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18217151\">[PubMed 18217151]</a></p>\n<p>21. Lotfi A, Schweiger MJ, Giugliano GR, et al, “High-Dose Atorvastatin Does Not Negatively Influence Clinical Outcomes among Clopidogrel Treated Acute Coronary Syndrome Patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Analysis,” <i>Am Heart J</i>, 2008, 155:954-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18440347\">[PubMed 18440347]</a></p>\n<p>22. Riondino S, Petrini N, Donato L, et al, “Effects of Rosuvastatin on Platelet Inhibition by Clopidogrel in Cardiovascular Patients,” <i>J Thromb Thrombolysis</i>, 2008, 28(2):151-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18636229\">[PubMed 18636229]</a></p>\n<p>23. Farid NA, Small DS, Payne CD, et al, “Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects,” <i>Pharmacotherapy</i>, 2008, 28:1483-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19025429\">[PubMed 19025429]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3609":"<p><b>Title</b> Vitamin K Antagonists / Leflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Leflunomide may enhance the anticoagulant effect of Vitamin K Antagonists. Leflunomide may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in INR and clinical anticoagulant effects in patients treated with warfarin following the initiation of leflunomide. Both increases and decreases in INR have been reported. The effects on acenocoumarol are unclear.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The INR of a warfarin-stable patient increased approximately 3-fold within 2 days of starting leflunomide therapy (100 mg/day as a loading dose).<sup>1</sup> The patient experienced gross hematuria and required warfarin discontinuation and vitamin K administration. He was subsequently restabilized on a lower dosage of warfarin while continuing on the maintenance dosage of leflunomide (20 mg/day). Another report describes the need to reduce weekly warfarin dosage by 22% to maintain therapeutic (nontoxic) INR following the initiation of leflunomide.<sup>2</sup><br><br>Conversely, the labeling for both leflunomide and the related product teriflunomide report that use of these agents with warfarin may result in a decrease in the peak INR of 25%.<sup>3,4</sup> Specific data to support this statement is not included.<br><br>The mechanism of this apparent interaction remains unclear. Leflunomide and teriflunomide reportedly did not alter the pharmacokinetics of S-warfarin (the more potent enantiomer), but these agents have been shown to be potential minor inducers of CYP1A2, which may increase the metabolism of the less potent R-warfarin, possibly explaining a possible decrease in INR.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. <i>Br Med J</i>. 2002;325(7376):1333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12468482\">[PubMed 12468482]</a></p>\n<p>2. Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. <i>Pharmacother</i>. 2006;26(6):868-871. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16716139\">[PubMed 16716139]</a></p>\n<p>3. Arava (leflunomide) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; August 2015.</p>\n<p>4. Aubagio (teriflunomide) [prescribing information]. Cambrdge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3610":"<p><b>Title</b> Tuberculin Tests / Vaccines (Live)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> If a parenteral form of a live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine. This should avoid the possibility of encountering false-negative PPD test results. Simultaneous administration of a parenteral live vaccine and a PPD skin test is an acceptable practice. PPD can also be administered and read prior to parenteral live vaccine administration; however, any such delay in vaccine administration is not optimal. Nonparenteral live vaccine administration is not expected to affect PPD results.<sup>5</sup> Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live*, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Severe infections and malnutrition can lead to anergy toward the tuberculin skin test (purified protein derivative, PPD).<sup>1,2,3</sup> Prior (recent) parenteral live vaccine (e.g., smallpox) administration has also been demonstrated to suppress PPD reactivity.<sup>4</sup> False-negative PPD reactions are possible. The ability of other live vaccines to similarly affect PPD is unknown. Simultaneous administration of parenteral measles vaccine and PPD does not appear to affect PPD test results.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Starr S and Berkovich S, “Effects of Measles, Gamma-globulin-modified Measles and Vaccine Measles on the Tuberculin Test,” <i>NEJM</i>, 1964, 270:386-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14087040\">[PubMed 14087040]</a></p>\n<p>2. Brickman HF, Beaudry PH, and Marks MI, “Timing of Tuberculin Tests in Relation to Immunization With Live Viral Vaccines,” <i>Pediatrics</i>, 1975, 55:392-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1143978\">[PubMed 1143978]</a></p>\n<p>3. Berkovich S and Starr S, “Effects of Live Type 1 Poliovirus Vaccine and Other Viruses on the Tuberculin Test,” <i>NEJM</i>, 1966, 274:67-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5294973\">[PubMed 5294973]</a></p>\n<p>4. CDC, “Recommendations for Using Smallpox Vaccine in a Pre-event Vaccination Program,” <i>MMWR</i>, February 26, 2003, 52:1-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12710832\">[PubMed 12710832]</a></p>\n<p>5. CDC, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP),” <i>MMWR</i>, 2002, 51:1-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11848294\">[PubMed 11848294]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3611":"<p><b>Title</b> Varicella Virus Vaccine / Smallpox Vaccine Live</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Smallpox Vaccine Live may enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate the administration of smallpox and varicella vaccines by at least 4 weeks.</p> \n<p><b>Discussion</b> Due to similarities in potential post-vaccination skin lesions, and other adverse effects, of smallpox and varicella vaccines, the CDC recommends that a minimum of 4 weeks separate their administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. CDC, “Recommendations for Using Smallpox Vaccine in a Pre-event Vaccination Program,” <i>MMWR</i>, February 26, 2003, 52:1-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12710832\">[PubMed 12710832]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3612":"<p><b>Title</b> Busulfan / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of increased busulfan toxicity if administered with an azole antifungal agent.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of busulfan was decreased approximately 20% in 13 patients undergoing a bone marrow transplant who were receiving busulfan with concomitant itraconazole as compared with no clearance changes in matched controls receiving either fluconazole (n=13) or no antifungal agent (n=26).<sup>1</sup><br><br>The precise mechanism for the apparent interaction is unclear, but since itraconazole is a strong inhibitor of CYP3A4 while fluconazole is a more moderate CYP3A4 inhibitor, inhibition of CYP3A4-mediated metabolism may be responsible. However, that such a minimal-to-moderate impact was observed with itraconazole and that no significant change was seen with the moderate inhibitor fluconazole suggests that any role for CYP3A4 in busulfan metabolism is likely relatively minor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). <i>Anticancer Res</i>. 1996;16(4A):2083-2088. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8712747\">[PubMed 8712747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3613":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium closely if this combination is used. Consider using an alternative to trimethoprim-sulfamethoxazole (TMP-SMZ) when possible, particularly in patients with other risk factors for hyperkalemia (eg, renal dysfunction, older age, use of other drugs or supplements that can increase potassium, use of higher-dose TMP-SMZ, etc.).</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> A population-based retrospective study in patients age 66 and older who were receiving an antiotensin II antagonist (ARB) or an angiotensin converting enzyme inhibitor (ACEI) found an increased odds of sudden death within 7 days of concurrent use of trimethoprim-sulfamethoxazole (TMP-SMZ) [adjusted OR=1.38 (95% CI: 1.09 to 1.76)] versus the comparator antibiotic amoxicillin.<sup>1</sup> Generally similar results were found using a time frame of sudden death within 14 days of TMP-SMZ or amoxicillin (adjusted OR=1.54). Although the authors attempted to adjust for differences among the cases and controls in their analysis, the groups differed on many potentially relevant measured variables (eg, renal disease, duration of ACEI or ARB use, etc.), raising at least some questions about the validity of these findings. Additionally, the study lacked a no-ACEI/no-ARB cohort, and serum potassium data were not collected or reported, both of which make the mechanism of any increase in sudden death unclear (ie, interaction vs. an independent TMP-SMZ effect, hyperkalemia-related, etc.). As an example of the benefit of a possible no-ACEI/no-ARB cohort, a prior study by this same group found that use of TMP-SMZ in beta-blocker users was associated with an increase in the odds for hyperkalemia [OR=5.1(2.8 to 9.4)], but an evaluation of a non-beta-blocker cohort found a similar risk with TMP-SMZ use, suggesting that the hyperkalemia risk was likely reflective of TMP-SMZ use alone and not of any interaction with beta-blockers.<sup>2</sup> An editorial accompanying this study looking at the risk of sudden death addresses some of these and other weaknesses and strengths of the study.<sup>3</sup><br><br>A previous nested case-control study in patients age 66 or older by the same group reported a 6.7-fold increase in the odds of hyperkalemia-associated hospitalization with TMP-SMZ than with concurrent use of amoxicillin.<sup>4</sup> Similarly, two retrospective studies of TMP-SMZ users identified concurrent use of ACEIs as one of several risk factors for TMP-SMZ-associated hyperkalemia,<sup>5,6</sup> and several case reports describe hyperkalemia attributed to the combined use of TMP-SMZ together with an ACEI or ARB.<sup>7,8,9,10,11,12</sup><br><br>Hyperkalemia is an established, though often unrecognized, side effect of trimethoprim.<sup>9,10,13,14</sup> Trimethoprim appears to reduce renal potassium excretion, acting similarly to the structurally similar potassium-sparing diuretic amiloride.<sup>13,14</sup> Patients at high risk of developing trimethoprim-induced hyperkalemia appear to include the higher dose trimethoprim, older age, renal insufficiency, use of prednisone, and concurrent use of drugs that can cause or exacerbate hyperkalemia (such as ACEIs, ARBs, aldosterone antagonists, etc.).<sup>4,5,6,15,16,17</sup><br><br>In contrast to these above reports, a nested case-control study of patients using potassium-altering medications concluded that trimethoprim was not a significant risk factor for hyperkalemia.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ</i>. 2014;349:g6196. (ePub ahead of print) doi: 10.1136/bmj.g6196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25359996\">[PubMed 25359996]</a></p>\n<p>2. Weir MA, Juurlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. <i>Clin J Am Soc Nephrol</i>. 2010;5(9):1544-1551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20595693\">[PubMed 20595693]</a></p>\n<p>3. Etminan M, Brophy JM. Antibiotics and sudden death in adults taking renin-angiotensin system blockers. <i>BMJ</i>. 2014;349:g6242. (ePub ahead of print) doi:10.1136/bmj.g6242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25360034\">[PubMed 25360034]</a></p>\n<p>4. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585070\">[PubMed 20585070]</a></p>\n<p>5. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. <i>Ann Pharmacother</i>. 2013;47(12):1618-1626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24259630\">[PubMed 24259630]</a></p>\n<p>6. Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. <i>Curr Drug Saf</i>. 2013;8(2):114-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23713542\">[PubMed 23713542]</a></p>\n<p>7. Lee SW, Park SW, Kang JM. Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers. <i>J Clin Anesth</i>. 2014;26(5):427-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25128254\">[PubMed 25128254]</a></p>\n<p>8. Juvet T, Gourineni VC, Ravi S, Zarich SW. Life-threatening hyperkalemia: a potentially lethal drug combination. <i>Conn Med</i>. 2013;77(8):491-493. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24156179\">[PubMed 24156179]</a></p>\n<p>9. Margassery S, Bastani B. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. <i>J Nephrol</i>. 2001;14(5):410-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11730276\">[PubMed 11730276]</a></p>\n<p>10. Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. <i>Gerontology</i>. 1999;45(4):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10394078\">[PubMed 10394078]</a></p>\n<p>11. Bugge JF. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. <i>J Intern Med</i>. 1996;240(4):249-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8918517\">[PubMed 8918517]</a></p>\n<p>12. Thomas RJ. Severe hyperkalemia with trimethoprim-quinapril. <i>Ann Pharmacother</i>. 1996;30(4):413-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8729901\">[PubMed 8729901]</a></p>\n<p>13. Don BR. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects. <i>Clin Nephrol</i>. 2001;55(1):45-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11200867\">[PubMed 11200867]</a></p>\n<p>14. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. <i>Ann Intern Med</i>. 1993;119(4):296-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8328738\">[PubMed 8328738]</a></p>\n<p>15. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. <i>Intern Med</i>. 2003;42(8):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12924488\">[PubMed 12924488]</a></p>\n<p>16. Mohan S, Jaitly M, Pogue VA, Cheng JT. Influence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. <i>J Antimicrob Chemother</i>. 2009;64(4):850-852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19656784\">[PubMed 19656784]</a></p>\n<p>17. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343:d5228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911446\">[PubMed 21911446]</a></p>\n<p>18. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. <i>Int J Clin Pharm</i>. 2013;35(6):1099-1104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23974985\">[PubMed 23974985]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3615":"<p><b>Title</b> Pegvisomant / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced pegvisomant efficacy in patients receiving opioid analgesics. Increased pegvisomant doses may be required.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> The pegvisomant prescribing information states that in clinical studies, patients taking opioids often needed higher pegvisomant doses to normalize insulin like growth factor concentrations compared with patients not receiving opioids.<sup>1</sup><br><br>The mechanism of this observed interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Somavert (pegvisomant) [prescribing information]. New York, NY: Pfizer Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3616":"<p><b>Title</b> Corticosteroids (Systemic) / Aprepitant</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: No dose adjustment for dexamethasone or methylprednisolone is required when only a single 40 mg dose of aprepitant is given. Dose reductions are recommended with the 130 mg IV single-dose regimen for highly emetogenic chemotherapy (Cinvanti brand).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of Corticosteroids (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. No dose adjustment is required for dexamethasone or methylprednisolone when only a single 40 mg dose of aprepitant is given. With use of the 130 mg IV single-dose regimen for highly emetogenic chemotherapy, a 50% reduction in dexamethasone dose or oral methylprednisolone dose on days 1 and 2 is recommended. For IV methylprednisolone, a 25% reduction in methylprednisolone dose is recommended. With other aprepitant regimens, oral dexamethasone or methylprednisolone doses should be reduced by 50%, and intravenous methylprednisolone doses should be reduced by 25%, to achieve corticosteroid concentrations similar to those achieved without aprepitant. Antiemetic regimens containing aprepitant and oral dexamethasone reflect this adjustment.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone*, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of oral dexamethasone (20 mg day 1 and 8 mg days 2-5) was increased 2.2-fold when coadministered with aprepitant (125 mg day 1 and 80 mg days 2-5).<sup>1,2,3</sup> The AUC of methylprednisolone (125 mg IV day 1 and 40 mg orally days 2 to 3) was increased by 34% on day 1 and 150% on day 3 when coadministered with aprepitant (125 mg day 1 and 80 mg days 2 to 3).<sup>1,2,3</sup> Doses used in clinical studies accounted for these pharmacokinetic changes in order to maintain desired corticosteroid exposure. The manufacturer proposes that aprepitant inhibits the CYP3A4 metabolism of the corticosteroids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emend (fosaprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017.</p>\n<p>2. Emend (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2017.</p>\n<p>3. Cinvanti (aprepitant) [prescribing information]. San Diego, CA: Heron Therapeutics; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3617":"<p><b>Title</b> Warfarin / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aprepitant may decrease the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects (ie, lower INR) for at least 2 weeks following initiation of aprepitant therapy. The INR may initially increase during the first week before persistently decreasing for up to 2-3 weeks. Monitoring should continue for at least 10 days following the completion of any aprepitant course.</p> \n<p><b>Discussion</b> The INR decreased by an average of 11% on study day 8 after completion of a 3-day course of aprepitant (125 mg day 1 and 80 mg days 2-3) in a study of 22 healthy volunteers stabilized on low-intensity warfarin (target INR of 1.3 to 1.8).<sup>1</sup> S-warfarin (more potent warfarin enantiomer) trough concentrations were also significantly decreased on study days 5 to 8 (by up to 34% on day 8), while no effect was noted in the concentrations of the less potent R-warfarin. In a study of 87 patients, the warfarin sensitivity index (WSI; average of INR value/average of daily warfarin dose) was monitored one week before and three weeks after aprepitant (125 mg day 1 and 80 mg days 2-3) administration.<sup>2</sup> The mean values of WSI increased from 0.51 to 0.74 after one week of aprepitant administration (suggesting an initial increase in warfarin effect), but decreased to 0.38 and 0.46 in the two weeks after (suggesting a decrease in warfarin effect and then a return to baseline). Similarly, the INR significantly decreased to less than 1.6 after aprepitant administration (125 mg day 1, 80 mg days 2-3) in 2 separate patients according to a published case report.<sup>3</sup> One patient experienced a transient increase in the INR to more than 2.6 prior to the decrease in INR.<br><br>Aprepitant prescribing information proposes that aprepitant may induce the CYP2C9 enzyme that is primarily responsible for the metabolism of S-warfarin (but not substantially involved in R-warfarin metabolism).<sup>4</sup> A study with the CYP2C9 substrate tolbutamide also reported evidence of CYP2C9 induction following a 3-day course of aprepitant, with maximum induction around day 8 (with day 1 corresponding to first dose of aprepitant).<sup>5</sup> By day 15 (last study observation), the inducing effect was still evident but was less than that observed on day 8. This time profile of CYP2C9 effects could be consistent with the observations of an early inhibition followed by a persistent induction lasting between 2 to 3 weeks following a 3-day course of aprepitant.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. <i>Eur J Clin Pharmacol</i>. 2005;61(5-6):341-346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15983826\">[PubMed 15983826]</a></p>\n<p>2. Takaki J, Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H. Assessment of drug-drug interaction between warfarin and aprepitant and its effects on PT-INR of patients receiving anticancer chemotherapy. <i>Biol Pharm Bull</i>. 2016; Mar 4 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26948084\">[PubMed 26948084]</a></p>\n<p>3. Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H. Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy. <i>Int J Clin Pharm</i>. 2014;36(6):1134-1137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25288146\">[PubMed 25288146]</a></p>\n<p>4. Emend (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc, November 2007.</p>\n<p>5. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. <i>J Clin Pharmacol</i>. 2004;44(3):215-223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14973304\">[PubMed 14973304]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3618":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aprepitant may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use of a nonhormonal contraceptive is recommended in patients being treated with aprepitant who desire effective contraception.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol (35 mcg daily in combination with norethindrone 1 mg) was decreased 43% when coadministered with aprepitant (100 mg/day) for 14 days.<sup>1</sup> The effects of a 3-day regimen have not been studied. Aprepitant may increase the metabolism of estrogens. If such is due to enzyme induction the effects may last for several days following the completion of a 3-day course of aprepitant. Whether or not the reduction in serum estrogen concentrations will result in therapeutic failure is unknown. Caution is advised. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emend [package insert]. Whitehouse Station, NJ: Merck &amp; Co, Inc, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3623":"<p><b>Title</b> RisperiDONE / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of RisperiDONE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider increasing the dose of risperidone (to no more than double the original dose) if carbamazepine is initiated/dose increased and monitor for reduced therapeutic effects of risperidone. Conversely, consider a risperidone dose reduction if carbamazepine is discontinued/dose decreased and monitor for increased risperidone effects/toxicity.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the risperidone prescribing information, coadministration of carbamazepine (approximately 573 mg per day) and risperidone (3 mg twice daily) decreased the AUC and maximum serum concentration of risperidone plus 9-hydroxyrisperidone (the active metabolite) 49% and 45%, respectively.<sup>1</sup> Similarly, in 2 other studies, coadministration of carbamazepine and risperidone decreased plasma concentrations of risperidone 50% to 68% and 9-hydroxyrisperidone 44% to 64%.<sup>2,3</sup> In a population model of risperidone pharmacokinetics developed from phase 1 and 3 trials, use of carbamazepine was associated with a 1.3-fold increase in risperidone clearance.<sup>4</sup> Additionally, several case reports describe patients who experienced worsening psychiatric symptoms upon the addition of carbamazepine to stable risperidone therapy or the development of risperidone toxicities upon carbamazepine withdrawal.<sup>5,6,7,8</sup> In contrast, one study reported that plasma concentrations of carbamazepine (mean dosage 625 mg per day) increased 19% in 8 patients with concomitant administration of risperidone (1 mg daily).<sup>9</sup> <br><br>Risperidone prescribing information states that concomitant administration with enzyme inducing drugs such as carbamazepine may decrease risperidone and 9-hydroxyrisperidone concentrations. Therefore, the dose of risperidone should be increased (to no more than double the original dose) when combined with carbamazepine.<sup>1</sup> <br><br>The mechanism of this interaction is unknown. Risperidone is primarily metabolized by CYP2D6 and carbamazepine does not appear to induce CYP2D6. However, induction of CYP3A4 or P-glycoprotein by carbamazepine may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2014.</p>\n<p>2. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. <i>Psychopharmacology (Berl)</i>. 2002;162(1):50-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12107617\">[PubMed 12107617]</a></p>\n<p>3. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. <i>Ther Drug Monit</i>. 2000;22(4):481-485. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10942191\">[PubMed 10942191]</a></p>\n<p>4. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. <i>J Pharmacokinet Pharmacodyn</i>. 2007;34(2):183-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136449\">[PubMed 17136449]</a></p>\n<p>5. Spina E, Scordo MG, Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. <i>J Clin Psychopharmacol</i>. 2001;21(1):108-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11199933\">[PubMed 11199933]</a></p>\n<p>6. Alfaro CL, Nicolson R, Lenane M, Rapoport JL. Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications. <i>Ann Pharmacother</i>. 2000;34(1):122-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10669197\">[PubMed 10669197]</a></p>\n<p>7. Takahashi H, Yoshida K, Higuchi H, Shimizu T. Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. <i>Clin Neuropharmacol</i>. 2001;24(6): 358-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11801812\">[PubMed 11801812]</a></p>\n<p>8. Strack DK, Leckband SG, Meyer JM. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. <i>J Psychiatr Pract</i>. 2009;15(6): 442-448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19934718\">[PubMed 19934718]</a></p>\n<p>9. Mula M, Monaco F. Carbamazepine-risperidone interactions in patients with epilepsy. <i>Clin Neuropharmacol</i>. 2002;25(2):97-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11981236\">[PubMed 11981236]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3625":"<p><b>Title</b> Bosentan / GlyBURIDE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> GlyBURIDE may enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of glyburide and bosentan. This combination is listed as a contraindication in the bosentan prescribing information.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, the AUC of glyburide (2.5 mg twice daily) decreased 40% when coadministered with bosentan (125 mg twice daily) for 5 days.<sup>1</sup> The AUC of bosentan (and its metabolites) decreased 20% to 30%. <br><br>The bosentan prescribing information states that an increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan.<sup>2</sup> For this reason, the concurrent use of bosentan and glyburide is contraindicated.<sup>2</sup> <br><br>The mechanism of liver enzyme elevation is unclear, but does not appear to be the result of a pharmacokinetic interaction. The mechanism by which bosentan decreased glyburide concentrations is likely due to bosentan-mediated induction of CYP2C9 and CYP3A4, enzymes responsible for glyburide metabolism.<sup>2,3</sup> The mechanism by which glyburide reduced bosentan concentrations is less clear, but glyburide-mediated induction of bosentan metabolism may contribute.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. <i>Clin Pharmacol Ther</i>. 2002; 71(4):253-262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11956508\">[PubMed 11956508]</a></p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p>3. van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. <i>Eur J Pharmacol</i>. 2002;450(2):115-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12206849\">[PubMed 12206849]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3628":"<p><b>Title</b> Vitamin K Antagonists / Bosentan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bosentan may increase the metabolism of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of warfarin if bosentan is initiated/dose increased, and increased effects if bosentan is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of warfarin enantiomers (26 mg single dose of racemic warfarin) were decreased 29% and 38% for S-warfarin and R-warfarin, respectively, when administered following a six-day course of bosentan (500 mg twice daily) in 12 normal subjects.<sup>1</sup> Prothrombin times were similarly reduced. A case report describes the development of subtherapeutic INR within 10 days of bosentan initiation in a patient previously stable on warfarin.<sup>2</sup> While continuing bosentan administration, the weekly warfarin dosage was eventually stablized 63% higher than the pre-bosentan dosage. An additional case series of 3 patients demonstrated decreased INR and a need for an increased dose of warfarin during bosentan therapy to maintain therapeutically acceptable INR values.<sup>3</sup> Weekly warfarin dose increases of approximately 30% to 40% were required. The distributor of bosentan reports that pulmonary hypertension patients receiving both drugs in clinical studies failed to demonstrate clinically significant changes in INR or warfarin dosages.<sup>4</sup> Bosentan is reported to induce CYP2C and 3A4 enzymes, and warfarin is metabolized by these enzymes. Particularly, S-warfarin, the more potent enantiomer, is metabolized by CYP2C9. Data regarding any effects of bosentan on acenocoumarol is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Weber C, Banken L, Birnboeck H, et al, “Effect of the Endothelin-receptor Antagonist Bosentan on the Pharmacokinetics and Pharmacodynamics of Warfarin,” <i>J Clin Pharmacol</i>, 1999, 39(8):847-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10434238\">[PubMed 10434238]</a></p>\n<p>2. Murphey LM and Hood EH, “Bosentan and Warfarin Interaction,” <i>Ann Pharmacother</i>, 2003, 37(7-8):1028-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12841813\">[PubMed 12841813]</a></p>\n<p>3. Haynes KB, “Case Series: Bosentan and Warfarin Interaction,” Abstract at American College of Clinical Pharmacy Annual Meeting, October 25, 2005, San Francisco, CA.</p>\n<p>4. Tracleer [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc, 1999.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3631":"<p><b>Title</b> Gefitinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concurrent use of ranitidine and sodium bicarbonate (to achieve and maintain gastric pH above pH 5.0) was associated with an average 44% decrease in gefitinib AUC.<sup>1,2</sup> Gefitinib labeling cautions that concurrent use of drugs that cause sustained elevations in gastric pH (including H2 receptor antagonists) may decrease gefitinib plasma concentrations, potentially reducing clinical efficacy.<sup>1,2</sup><br><br>The mechanism for this possible interaction is not certain, but gefitinib aqueous solubility has been shown to decline with increases in gastric pH, particularly as pH increases between pH 4.0 and pH 6.0.<sup>1,2</sup> This could decrease the extent of gefitinib absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2015.</p>\n<p>2. Iressa (gefitinib) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3632":"<p><b>Title</b> Vitamin K Antagonists / Gefitinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gefitinib may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects if gefitinib is initiated/dose increased, and decreased effects if gefitinib is discontinued/dose decreased. The effects of gefitinib on anisindione are unknown.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturer reports that some patients receiving concomitant warfarin and gefitinib experienced increased INR and/or bleeding.<sup>1</sup> A case report describes a need to decrease the warfarin dose in a patient from 4 to 2.5 mg daily following the initiation of gefitinib in order to maintain a desired INR value.<sup>2</sup> A second case report in the same paper failed to demonstrate any effect. A mechanism for the observed warfarin-related changes in the former case is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iressa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2003.</p>\n<p>2. Onoda S, Mitsufuji H, Yanase N, et al, “Drug Interaction Between Gefitinib and Warfarin,” <i>Jpn J Clin Oncol</i>, 2005, 35(8):478-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16006576\">[PubMed 16006576]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3633":"<p><b>Title</b> Indinavir / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of indinavir if a proton pump inhibitor is initiated/dose increased, or increased effects if a proton pump inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole*, Pantoprazole, RABEprazole, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a retrospective review of 9 patients receiving both indinavir (800mg three times daily) and omeprazole (20-40mg daily), 4 (44%) had lower indinavir AUC values than expected, based on population values.<sup>1</sup> Similarly, in a prospective clinical study of 14 HIV-negative volunteers, indinavir (800mg x1) AUC and maximum plasma concentrations (Cmax) were 34% and 29% lower, respectively, when administered after 7 days of omeprazole 20mg/day.<sup>2</sup> When administered following 7 days of omeprazole 40mg/day, indinavir AUC and Cmax were 47% and 41% lower, respectively, as compared to administration after 7 days of placebo.<br><br>The mechanism of this apparent interaction is likely decreased indinavir dissolution and absorption due to the omeprazole-related increase in gastric pH. Indinavir dissolution and absorption has been previously shown to be optimal in an acidic environment.<sup>3</sup> As a result, it is expected that other acid-reducers, such as other proton pump inhibitors and the histamine-2 antagonists, would cause a similar interaction if combined with indinavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Burger DM, Hugen PW, Kroon FP, et al, “Pharmacokinetic Interaction Between the Proton Pump Inhibitor Omeprazole and the HIV Protease Inhibitor Indinavir,” <i>AIDS</i>, 1998, 12(15):2080-2. [PMID: 9814882]</p>\n<p>2. Tappouni HL, Rublein JC, Donovan BJ, et al, “Effect of Omeprazole on the Plasma Concentrations of Indinavir When Administered Alone and in Combination with Ritonavir,” <i>Am J Health Syst Pharm</i>, 2008, 65(5):422-8. [PMID: 18281734]</p>\n<p>3. Lin JH, Chen IW, Vastag KJ, et al, “pH-Dependent Oral Absorption of L-735,524, a Potent HIV Protease Inhibitor, in Rats and Dogs,” <i>Drug Metab Dispos</i>, 1995, 23(7):730-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7587962\">[PubMed 7587962]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3635":"<p><b>Title</b> Digoxin / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole*, Pantoprazole*, RABEprazole*, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of digoxin (1 mg oral single dose) was increased approximately 10% when administered following an 11-day course of omeprazole (20 mg/day). The increase was still within accepted range for bioequivalence. Of note, the individual increase was approximately 30% in 2 study subjects.<sup>1</sup> Pantoprazole (40 mg/day for 5 days) caused a similar increase in mean digoxin AUC (beta-acetyldigoxin 200 mcg twice daily) in 18 healthy subjects.<sup>2</sup> A 14 day concurrent therapy study with rabeprazole (20 mg/day) and digoxin (375 mcg/day) in 16 patients found a mean 21% increase in digoxin AUC.<sup>3</sup> In a case study, a 65 year old woman experienced digoxin toxicity and an elevated serum digoxin level (increased from 1.1 to 3.9) 3 months after starting omperazole 20 mg.<sup>4</sup> She had been stable on digoxin 0.625 mg for 6 years prior. However, the increase in digoxin occurred long after omeprazole was at steady state, and the increase in digoxin level (over 300%) was markedly higher than that noted in other trials (30%). Therefore this case may have had other factors that led to the increase in digoxin.<br><br>The apparent mechanism of these changes is unclear, but thesechanges do not appear to pose any significant clinical concern.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Oosterhuis B, Jonkman JH, Andersson T, et al, “Minor Effect of Multiple Dose Omeprazole on the Pharmacokinetics of Digoxin After a Single Oral Dose,” <i>Br J Clin Pharmacol</i>, 1991, 32(5):569-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1954072\">[PubMed 1954072]</a></p>\n<p>2. Hartmann M, Huber R, Bliesath H, et al, “Lack of Interaction Between Pantoprazole and Digoxin at Therapeutic Doses in Man,” <i>Int J Clin Pharmacol Ther</i>, 1995, 33(9):481-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520804\">[PubMed 8520804]</a></p>\n<p>3. Humphries TJ, Nardi, RV, Lazar JD, et al, “Drug-drug Interaction Evaluation of Rabeprazole Sodium: A Clean/Expected Slate?” <i>Gut</i>, 1996, 39(Suppl 3):A47.</p>\n<p>4. Kiley CA, Cragin DJ, Roth BJ, “Omeprazole-Associated Digoxin Toxicity,” <i>South Med J</i>, 2007, 100(4):400-2. [PMID: 17458401]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3638":"<p><b>Title</b> Repaglinide / Gemfibrozil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors (Strong)): The magnitude of this drug interaction may be much greater in the presence of a strong CYP3A4 inhibitor (e.g. itraconazole).</p></li>\n <li><p><b>Genotype</b>: The magnitude of this interaction may be dependent on SLCO1B1 genotype.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may increase the serum concentration of Repaglinide. The addition of itraconazole may augment the effect of gemfibrozil on repaglinide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of gemfibrozil with repaglinide is contraindicated according to gemfibrozil prescribing information.</p> \n<p><b>Discussion</b> Repaglinide (0.25 mg single dose) AUC was increased 8.1-fold and its half-life was prolonged from 1.3 hours to 3.7 hours in 12 normal subjects when administered following 3 days of gemfibrozil (600 mg twice daily).<sup>1</sup> When the azole antifungal itraconazole was given together with gemfibrozil for 3 days prior to repaglinide, the repaglinide AUC increased 19.4-fold and its half-life was further prolonged to 6.1 hrs. These effects are in contrast to the relatively minor effects observed with itraconazole alone (1.4-fold increase in repaglinide AUC and no significant change in repaglinide half-life). Additionally, the significant pharmacokinetic effects of both gemfibrozil combinations appeared to be associated with prolonged and more potent hypoglycemic effects of repaglinide.<sup>1</sup> Novo Nordisk Canada reports that 5 cases of hypoglycemia during concomitant therapy with repaglinide and gemfibrozil are contained in their international safety database.<sup>2</sup> <br><br>Of note, there appears to be considerable patient-to-patient variability in the magnitude of the gemfibrozil-repaglinide interaction, with genetic variation accounting for at least some of this variability. Specifically, a study in volunteers with known <i>SLCO1B1</i> (codes for the import transporter OATP1B1) genotypes found that individuals with one or more copies of a specific gene variant displayed a 54-56% greater increase in repaglinide AUC with concurrent gemfibrozil as compared to individuals homozygous for the wild-type version.<sup>3</sup> Several other studies have documented that the OATP1B1 transporter is an important determinant of repaglinide pharmacokinetics.<sup>4,5</sup><br><br>According to gemfibrozil prescribing information, concurrent use of gemfibrozil with repaglinide is contraindicated due to the risk for increased repaglinide concentrations and greater hypoglycemic effects.<sup>6</sup><br><br>The mechanism by which gemfibrozil interacts with repaglinide appears to be primarily inhibition of CYP2C8-mediated metabolism of repaglinide by gemfibrozil glucuronide.<sup>7,8,9,10</sup> Both CYP2C8 and CYP3A4 appear to account for most of repaglinide metabolism,<sup>7,8</sup> and gemfibrozil glucuronide has been shown to be a potent inhibitor of CYP2C8.<sup>9,10</sup> This CYP2C8 inhibition appears to result from binding of the gemfibrozil glucuronide to the CYP2C8 enzyme, resulting in a potent and long-lasting (i.e., for more than 12 hours after the last gemfibrozil dose) inhibition.<sup>9</sup> The apparently synergistic interaction between repaglinide and the combination of gemfibrozil and itraconazole<sup>1</sup> is likely the result of combined inhibition of both CYP2C8 (by gemfibrozil) and CYP3A4 (by itraconazole). It is predicted that other potent CYP3A4 inhibitors would have a similar effect when given with the combination of gemfibrozil and repaglinide. One additional factor to consider regarding the mechanism of this interaction is possible inhibition by gemfibrozil of repaglinide uptake into the hepatocytes via inhibition of the OATP1B1 transporter. As previously described, repaglinide is transported by OATP1B1,<sup>3,4</sup> and gemfibrozil has been shown to be capable of inhibiting OATP1B1.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, Neuvonen M, et al, “Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics and Pharmacodynamics of Repaglinide: Potentially Hazardous Interaction Between Gemfibrozil and Repaglinide,” <i>Diabetologia</i>, 2003, 46(3):347-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12687332\">[PubMed 12687332]</a></p>\n<p>2. Dear Health Professional Letter distributed by Novo Nordisk Canada dated July 18, 2003: located at http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/repaglinide_prof_e.htm.</p>\n<p>3. Kalliokoski A, Backman J, Kurkinen K, et al, “Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism,” <i>Clin Pharmacol Ther</i>, 2008, 84(4):488-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19238654\">[PubMed 19238654]</a></p>\n<p>4. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al, “Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide,” <i>J Clin Pharmacol</i>, 2008, 48:311-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18187595\">[PubMed 18187595]</a></p>\n<p>5. Rodriguez-Antona C, Niemi M, Backman JT, et al, “Characterization of Novel CYP2C8 Haplotypes and Their Contribution to Paclitaxel and Repaglinide Metabolism,” <i>Pharmacogenomics J</i>, 2008, 8:268-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17923851\">[PubMed 17923851]</a></p>\n<p>6. Prescribing information. Lopid (gemfibrozil). New York, NY: Pfizer Inc, November 2008.</p>\n<p>7. Kajosaari LI, Laitila J, Neuvonen PJ, et al, “Metabolism of Repaglinide by CYP2C8 and CYP3A4 in Vitro: Effect of Fibrates and Rifampicin,” <i>Basic Clin Pharmacol Toxicol</i>, 2005, 97:249-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16176562\">[PubMed 16176562]</a></p>\n<p>8. Bidstrup TB, Bjornsdottir I, Sidelmann UG, et al, “CYP2C8 and CYP3A4 Are the Principal Enzymes Involved in the Human in Vitro Biotransformation of the Insulin Secretagogue Repaglinide,” <i>Br J Clin Pharmacol</i>, 2003, 56:305-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12919179\">[PubMed 12919179]</a></p>\n<p>9. Tornio A, Niemi M, Neuvonen M, et al, “The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 H after the Dose: Evidence for Mechanism-Based Inhibition of CYP2C8 in Vivo,” <i>Clin Pharmacol Ther</i>, 2008, 84(3):403-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18388877\">[PubMed 18388877]</a></p>\n<p>10. Ogilvie BW, Zhang D, Li W, et al, “Glucuronidation Converts Gemfibrozil to a Potent, Metabolism-Dependent Inhibitor of CYP2C8: Implications for Drug-Drug Interactions,” <i>Drug Metab Dispos</i>, 2006, 34:191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16299161\">[PubMed 16299161]</a></p>\n<p>11. Shitara Y, Hirano M, Sato H, et al, “Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction Between Cerivastatin and Gemfibrozil,” <i>J Pharmacol Exp Ther</i>, 2004, 311: 228-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15194707\">[PubMed 15194707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3640":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Nafcillin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nafcillin may increase the metabolism of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduced serum estrogen concentrations, and therefore reduced contraceptive efficacy, appears possible during concomitant therapy with nafcillin. This potential interaction should be avoided, if possible. Patients should be instructed to use alternative, nonhormonal forms of contraception during nafcillin therapy. Alternative therapy to nafcillin could also be considered. If agents are used concomitantly, monitor for signs of menstrual irregularities, including breakthrough bleeding (which may indicate reduced hormone concentrations) noting that the absence of such signs does not indicate therapeutic success.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Anecdotal data indicate the possibility that penicillin antibiotics might inhibit the efficacy of oral contraceptives. These are almost exclusively related to estrogen-containing products.<sup>1,2</sup> A 2-month study in 11 subjects taking an oral contraceptive (containing 50 mcg estrogen) and ampicillin showed no effect of the ampicillin on the ovulation suppression effect of the contraceptive.<sup>3</sup> A paucity of epidemiologic data suggests that the incidence of pregnancy that occurs with concomitant antibiotic and hormonal contraception is no greater than the incidence during the use of hormonal contraception alone without concomitant antibiotics.<sup>2,4,5</sup> A thorough review of this topic was conducted by Archer et al.<sup>6</sup> They concluded that “available scientific and pharmacokinetic data do not support the hypothesis that antibiotics (with the exception of rifampin) lower the contraceptive efficacy of oral contraceptives.” A year 2000 Practice Bulletin of the American College of Obstetrics and Gynecology recommends the use of nonhormonal contraceptives only with the concomitant use of rifampin or griseofulvin.<sup>7</sup> A proposed (yet otherwise unproven) mechanism for this potential interaction is based on the antibiotic's ability to reduce gut bacteria which are important for hydrolysis of conjugated estrogen, which subsequently permits the reabsorption of the estrogen (ie, enterohepatic circulation is interrupted, resulting in lower serum concentrations of the estrogen). No supporting evidence is available. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.<br><br>In contrast to the above data, nafcillin may offer an additional potential mechanism for interaction with oral contraceptives. Nafcillin appears to effectively induce CYP3A4 isoenzymes<sup>8,9,10</sup> and, therefore, may reduce serum estrogen concentrations. No reports confirming these effects or associated problems have been identified. However, caution should be exercised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Back DJ, Breckenridge AM, MacIver M, et al, “The Effect of Ampicillin on Oral Contraceptive Steroids in Women,” <i>Br J Clin Pharmacol</i>, 1982, 14:43-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6809025\">[PubMed 6809025]</a></p>\n<p>2. Back DJ, Grimmer FM, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25(5):527-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3408633\">[PubMed 3408633]</a></p>\n<p>3. Friedman CI, Huneke AL, Kim MH, et al, “The Effect of Ampicillin on Oral Contraceptive Effectiveness,” <i>Obstet Gynecol</i>, 1980, 55:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7188714\">[PubMed 7188714]</a></p>\n<p>4. Sparrow MJ, “Pill Method Failures,” <i>N Z Med J</i>, 1987, 100:102-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3470667\">[PubMed 3470667]</a></p>\n<p>5. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9146531\">[PubMed 9146531]</a></p>\n<p>6. Archer JS and Archer DF, “Oral Contraceptive Efficacy and Antibiotic Interaction: A Myth Debunked,” <i>J Am Acad Dermatol</i>, 2002, 46:917-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12063491\">[PubMed 12063491]</a></p>\n<p>7. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11732484\">[PubMed 11732484]</a></p>\n<p>8. Jamal SK, et al, “Nafcillin Is a Potent Inducer of Cytochrome P4503A Activity in Humans,” <i>Clin Pharmacol Ther</i>, 1998, 63:151.</p>\n<p>9. Lang CC, Jamal SK, Mohamed Z, et al, “Evidence of an Interaction Between Nifedipine and Nafcillin in Humans,” <i>Br J Clin Pharmacol</i>, 2003, 55:588-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814453\">[PubMed 12814453]</a></p>\n<p>10. Yasuda K, Ranade A, Venkataramanan R, et al, “A Comprehensive In Vitro and In Silico Analysis of Antibiotics that Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine,” <i>Drug Metab Dispos</i>, 2008, 36(8):1689-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18505790\">[PubMed 18505790]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3641":"<p><b>Title</b> Levothyroxine / Raloxifene</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Raloxifene may decrease the absorption of Levothyroxine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider separating the daily doses of raloxifene and levothyroxine by several hours. Monitor for reduced effects of levothyroxine (ie, monitor for signs and symptoms of hypothyroidism) and reduced serum concentrations of thyroxine if raloxifene and levothyroxine are concomitantly administered.</p> \n<p><b>Discussion</b> Case Report. Concomitant administration of levothyroxine and raloxifene resulted in increasing levothyroxine requirements in 79-year old woman with chronic primary hypothyroidism.<sup>1</sup> Therapy challenge and dechallenge, along with serial measurements of serum thyroxine, help to confirm the observation that raloxifene decreases levothyroxine absorption. The mechanism of this apparent interaction is unclear. However, a number of related observations provide valuable insight.<br><br>T4 is actively transported into human fibroblasts, hepatocytes and other cells.<sup>2,3</sup> Gastrointestinal epithelial cell may serve as a reservoir for T4, and uptake is likely transporter mediated.<sup>3,4</sup> Additionally, levothyroxine may be subject to CYP3A4 metabolism.<sup>5</sup> Raloxifene, through CYP3A4 inhibition and/or direct or indirect (eg, through estrogen receptor modulation) effects on transporters may reduce levothyroxine uptake into GI epithelial cells and subsequent systemic distribution.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Siraj ES, Gupta MK, and Reddy SS, “Raloxifene Causing Malabsorption of Levothyroxine,” <i>Arch Intern Med</i>, 2003, 163(11):1367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12796075\">[PubMed 12796075]</a></p>\n<p>2. Docter R, Krenning EP, Bernard HF, et al, “Active Transport of Iodothyronines into Human Cultured Fibroblasts,” <i>J Clin Endocrinol Metab</i>, 1987, 65(4):624-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2443527\">[PubMed 2443527]</a></p>\n<p>3. Powell KA, Mitchell AM, Manley SW, et al, “Different Transporters for Tri-iodothyronine (T(3)) and Thyroxine (T(4)) in the Human Choriocarcinoma Cell Line, JAR,” <i>J Endocrinol</i>, 2000, 167(3):487-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11115776\">[PubMed 11115776]</a></p>\n<p>4. Hays MT,“Thyroid Hormone and the Gut,” <i>Endocr Res</i>, 1988, 14(2-3):203-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3049061\">[PubMed 3049061]</a></p>\n<p>5. Jonderko G, Jonderko K, Marcisz C, et al, “Effect of Cimetidine and Ranitidine on Absorption of [125I]Levothyroxine Administered Orally,” <i>Acta Pharmacologica Sinica</i>, 1992, 13(5):391-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1300037\">[PubMed 1300037]</a></p>\n<p>6. Chen Q, Ngui JS, Doss GA, et al, “Cytochrome P450 3A4-mediated Bioactivation of Raloxifene: Irreversible Enzyme Inhibition and Thiol Adduct Formation,” <i>Chem Res Toxicol</i>, 2002, 15(7):907-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12119000\">[PubMed 12119000]</a></p>\n<p>7. Kemp DC, Fan PW, and Stevens JC, “Characterization of Raloxifene Glucuronidation in Vitro: Contribution of Intestinal Metabolism to Presystemic Clearance,” <i>Drug Metab Dispos</i>, 2002, 30:694-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12019197\">[PubMed 12019197]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3642":"<p><b>Title</b> Tenofovir Disoproxil Fumarate / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Histamine H2-Antagonists): Patients using this combination together with an H2-receptor antagonist will likely require additional therapy adjustments.</p></li>\n <li><p><b>Age</b>: Pediatric patients, and in particular those weighing less than 40 kg, may require special dosing or other therapy adjustment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> According to atazanavir prescribing information, when combined therapy with tenofovir is required, a combination of atazanavir (300 mg) with ritonavir (100 mg) and tenofovir disoproxil fumarate (300 mg) should be used. This combination should be given as a single daily dose with food. Atazanavir without ritonavir should not be used with tenofovir. Additional therapy modification appears necessary for patients also using an H2-receptor antagonist, for many pediatric patients, and for pregnant patients. Patients using atazanavir (with ritonavir) and tenofovir and an H2-receptor antagonist should use an atazanavir/ritonavir dose of 400 mg/100 mg once/day. There is insufficient data available to recommend dosing for this combination in pediatric patients who weigh less than 40 kg. Treatment-experienced pregnant women who are in their second or third trimester and who are to receive atazanavir/ritonavir with tenofovir should be treated with an atazanavir/ritonavir dose of 400 mg/100 mg once/day. There is insufficient data to recommend dosing for concurrent use of atazanavir/ritonavir plus tenofovir and an H2-receptor antagonist in treatment-experienced pregnant women. Coadministration of atazanavir with the Atripla combination product (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) is not recommended according to the Atripla prescribing information.</p> \n<p><b>Discussion</b> The AUC and minimum serum concentration (Cmin) of atazanavir were decreased by approximately 25% and 23-40%, respectively, when coadministered with tenofovir disoproxil fumarate.<sup>1,2,3</sup> Use of this combination only together with ritonavir is recommended in an effort to maintain therapeutic atazanavir concentrations. Even with concurrent tenofovir, the atazanvir AUC and Cmin obtained following use of atazanavir/ritonavir 300 mg/100 mg daily was several-fold higher than those obtained following use of atazanavir 400 mg/day alone.<sup>1,2</sup> A retrospective review of 308 atazanavir Cmins from 238 patients concluded that patients treated with ritonavir-boosted atazanavir and tenofovir were more likely to have therapeutic Cmin values than were those treated with unboosted atazanavir and tenofovir (OR=2.3).<sup>4</sup> However, among all patients receiving unboosted atazanavir there was no significant difference in proportion with a therapeutic Cmin between those also receiving tenofovir and those who were not.<br><br>Two studies in pregnant patients also found generally similar results. In one study of pregnant women in their second (atazanavir/ritonavir 300 mg/100 mg daily) or third trimester (atazanavir/ritonavir 400 mg/100 mg daily) reported an average 14% and 17.5% lower atazanavir AUC, respectively, among those receiving concurrent tenofovir disoproxil fumarate.<sup>5</sup> In another study, a larger percentage of patients had an atazanavir AUC or Cmin below target if they were also receiving tenofovir disoproxil fumarate (55% vs. 33% and 15% vs. 6%, respectively) in a study of 2 cohorts of pregnant women receiving atazanavir/ritonavir 300 mg/100 mg daily with or without tenofovir.<sup>6</sup><br><br>The mechanism of this apparent drug interaction is also unknown, though the atazanavir clearance has been shown to be increased by concurrent tenofovir (relative to nucleoside reverse transcriptase inhibitors),<sup>7</sup> suggesting at least a possible mechanism for these observations.<br><br>Additionally, the tenofovir AUC is increased by an average of 37% with concurrent atazanavir/ritonavir (300 mg/100 mg daily) and by an average of 24% with unboosted atazanavir (400 mg/day).<sup>2</sup> The tenofovir maximum serum concentration (Cmax) was similarly increased by 14-34% with concurrent atazanavir. The mechanism of this interaction is uncertain but may involve atazanavir-mediated inhibition of tenofovir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, August 2013.</p>\n<p>2. Prescribing information. Viread (tenofovir). Foster City, CA: Gilead Sciences, Inc., October 2013.</p>\n<p>3. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. <i>Antimicrob Agents Chemother</i>. 2004;48(6):2091-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15155205\">[PubMed 15155205]</a></p>\n<p>4. Fournier C, Higgins N, Thomas R, et al. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. <i>Ther Drug Monit</i>. 2013;35(2):264-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23503454\">[PubMed 23503454]</a></p>\n<p>5. Kreitchmann R, Best BM, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. <i>J Acquir Immune Defic Syndr</i>. 2013;63(1):59-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23392467\">[PubMed 23392467]</a></p>\n<p>6. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. <i>J Acquir Immune Defic Syndr</i>. 2011;56(5):412-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21283017\">[PubMed 21283017]</a></p>\n<p>7. Dailly E, Tribut O, Tattevin P, et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. <i>Eur J Clin Pharmacol</i>. 2006;62(7):523-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16763827\">[PubMed 16763827]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3643":"<p><b>Title</b> Amiodarone / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/effects of amiodarone if orlistat is coadministered. The benefit of separating the doses of these drugs is unknown.</p> \n<p><b>Discussion</b> In 16 healthy volunteers, the amiodarone (1,200 mg single oral dose) AUC and maximum serum concentration were 23% and 24% lower, respectively, when coadministered on day 4 to 6 of treatment with orlistat (120 mg three times daily x 14 days) compared with 16 other volunteers who received amiodarone alone.<sup>1</sup> There was no difference in the half-life of amiodarone between groups.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but reduced absorption of amiodarone, a highly lipophilic drug, by orlistat is the likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. <i>J Clin Pharmacol</i>. 2003;43(4):428-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12723464\">[PubMed 12723464]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3647":"<p><b>Title</b> Thiazolidinediones / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Gemfibrozil may decrease the metabolism of Thiazolidinediones. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil. Monitor for increased thiazolidinedione effects if gemfibrozil is initiated/dose increased, or decreased effects if gemfibrozil is discontinued/dose decreased.</p>\n<div>\n <p><b>Thiazolidinediones Interacting Members</b> Lobeglitazone, Pioglitazone*, Rosiglitazone*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of rosiglitazone (4 mg single dose) was increased 2.3-fold in 10 healthy volunteers when administered on day 3 of a 4-day regimen of gemfibrozil (600 mg twice daily).<sup>1</sup> The N-desmethylrosiglitazone/rosiglitazone ratio was decreased by 38%. Three studies in healthy volunteers also demonstrated increases in the AUC of pioglitazone (2.3-3.4 fold) during gemfibrozil coadministration (600 mg twice daily).<sup>2,3,4</sup> <br><br>Gemfibrozil likely inhibits the CYP2C8 metabolism of both pioglitazone and rosiglitazone.<sup>5</sup> Pioglitazone prescribing information recommends limiting pioglitazone maximum adult dose to 15 mg/day during gemfibrozil treatment,<sup>4</sup> and rosiglitazone prescribing information recommends considering dose reductions but does not give specific limits.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, Granfors M, et al, “Gemfibrozil Considerably Increases the Plasma Concentrations of Rosiglitazone,” <i>Diabetologia</i>, 2003, 46(10):1319-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12898007\">[PubMed 12898007]</a></p>\n<p>2. Jaakkola T, Backman JT, Neuvonen M, et al, “Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone,” <i>Clin Pharmacol Ther</i>, 2005, 77(5):404-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15900286\">[PubMed 15900286]</a></p>\n<p>3. Deng LJ, Wang F, and Li HD, “Effect of Gemfibrozil on the Pharmacokinetics of Pioglitazone,” <i>Eur J Clin Pharmacol</i>, 2005, 61(11):831-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16283275\">[PubMed 16283275]</a></p>\n<p>4. Prescribing information. Actos (pioglitazone). Deerfield, IL: Takeda Pharmaceuticals America, Inc., January 2012.</p>\n<p>4. Ogilvie BW, Zhang D, Li W, et al, “Glucuronidation Converts Gemfibrozil To a Potent, Metabolism-Dependent Inhibitor of CYP2C8: Implications for Drug-Drug Interactions,” <i>Drug Metab Dispos</i>, 2006, 34(1):191-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16299161\">[PubMed 16299161]</a></p>\n<p>6. Prescribing information. Avandia (rosiglitazone). Research Triangle Park, NC: GlaxoSmithKline, 11/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3648":"<p><b>Title</b> Pentostatin / Fludarabine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fludarabine may enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fludarabine with pentostatin.</p> \n<p><b>Discussion</b> In a clinical trial evaluating concomitant use of pentostatin with fludarabine in the treatment of refractory chronic lymphocytic leukemia, four of six individuals developed severe or fatal pulmonary toxicity.<sup>1</sup> Additional information regarding this observation is lacking. <br><br>A mechanism for this potential drug interaction is unclear. As both agents may cause pulmonary toxicity, one might consider the possibility of a pharmacodynamic interaction and the potential for additive adverse effects. Additionally, one might consider the disease state role in the observed negative outcomes. Though not specifically contraindicated in either pentostatin or fludarabine labeling, it is recommended that these two agents not be used together.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pentostatin. Bedford, OH: Ben Venue Laboratories, Inc., August 2006.</p>\n<p>2. Prescribing information. Fludara (Fludarabine). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., February 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3649":"<p><b>Title</b> Alfuzosin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Alfuzosin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy subjects, the AUC and maximum serum concentration of alfuzosin (5 mg single dose) was unchanged when administered following 1 and 20 days of cimetidine (1 g/day).<sup>1</sup> The half-life of alfuzosin decreased 14%.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1993;31(11):568-571. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7904983\">[PubMed 7904983]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3650":"<p><b>Title</b> Didanosine / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption. Atazanavir may decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine. This recommendation applies to both buffered didanosine products and enteric coated didanosine products.</p> \n<p><b>Discussion</b> The AUC of atazanavir (400 mg single dose) was reduced by nearly 90% in 31 normal subjects when administered simultaneously with didanosine buffered tablets and stavudine.<sup>1</sup> No effect on atazanavir AUC was observed when administered 1 hour after didanosine/stavudine administration. Atazanavir solubility is greatly reduced with increased pH, as would be the case in the presence of didanosine buffered tablets.<br><br>Additionally, the AUC of didanosine (400 mg daily via enteric coated capsules) was reduced 34% in 65 patients when coadministered with atazanavir (400 mg daily) or atazanavir/ritonavir (300 mg/100 mg daily).<sup>1</sup> Didanosine maximum serum concentrations (Cmax) were also decreased by 36-38% in these studies. The mechanism of this pharmacokinetic interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, November 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3651":"<p><b>Title</b> Atazanavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Atazanavir. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Due to the risk of antiviral failure, concomitant administration of rifampin and atazanavir (with or without ritonavir) should be avoided. This combination is contraindicated according to atazanavir prescribing information.</p> \n<p><b>Discussion</b> Concurrent use of rifampin (600 mg/day) with either atazanavir 300 mg every 12 hours or atazanavir 400 mg every 12 hours was associated with 95% and 86% reductions in minimum atazanavir concentrations (Cmin), respectively, in a study of 10 healthy volunteers.<sup>1</sup> Similarly, a small study of 3 HIV-positive patients with tuberculosis reported that even with concurrent ritonavir (100 mg daily), atazanavir Cmin was below the minimum recommended value more than 50% of the time when atazanavir (300 mg) was coadministered with rifampin (600 mg/day).<sup>2</sup> Additional data support the significance of this interaction, showing an average 97% reduction in atazanavir Cmin when atazanvir (300 mg/day) and ritonavir (100 mg/day) were administered with rifampin (600 mg/day).<sup>3,4</sup> Atazanavir AUC was also reduced by an average of 72% in this study. Of note, increasing the ritonavir dose to 200 mg/day or increasing both the atazanavir and ritonavir doses (to 400 mg/200 mg daily) both failed to overcome the effects of rifampin, as atazanavir Cmin and AUC were still reduced by 94-93% and 54-46%, respectively.<sup>3</sup> These data are generally similar to those reported for other protease inhibitors when combined with rifampin.<br><br>The effects are likely related to the ability of rifampin to induce CYP3A4-mediated metabolism of atazanavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Acosta EP, Kendall MA, Gerber JG, et al, “Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily,” <i>Antimicrob Agents Chemother</i>, 2007, 51(9):3104-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17576825\">[PubMed 17576825]</a></p>\n<p>2. Mallolas J, Sarasa M, Nomdedeu M, et al, “Pharmacokinetic Interaction Between Rifampicin and Ritonavir-Boosted Atazanavir in HIV-Infected Patients,” <i>HIV Med</i>, 2007, 8(2):131-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352770\">[PubMed 17352770]</a> </p>\n<p>3. Burger DM, Agarwala S, Child M, et al, “Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers,” <i>Antimicrob Agents Chemother</i>, 2006, 50(10):3336-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005814\">[PubMed 17005814]</a></p>\n<p>4. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3652":"<p><b>Title</b> Theophylline / Zileuton</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zileuton may increase the serum concentration of Theophylline. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the dosage of theophylline by 50% upon initiation of zileuton therapy. If theophylline is added to existing zileuton therapy, a lower starting dose with subsequent monitoring should be considered. Along with dose adjustment, monitor for increased serum concentrations and effects of theophylline if combined with zileuton.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 16 healthy volunteers, administration of zileuton (800 mg twice daily) increased the theophylline (200 mg 4 times daily) maximum serum concentration 75% and decreased the theophylline clearance 49%.<sup>1</sup> The number of reported theophylline-related adverse effects was greater when coadministered with zileuton (44 vs 8).<sup>1</sup> <br><br>Prescribing information for zileuton states that upon initiation of zileuton therapy, the theophylline dose should be reduced by 50% and plasma theophylline concentrations should be closely monitored.<sup>2</sup><br><br>The mechanism of this interaction is likely zileuton inhibition of CYP1A2, an enzyme responsible for theophylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. <i>Clin Pharmacokinet</i>. 1995;29(suppl 2):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8620674\">[PubMed 8620674]</a></p>\n<p>2. Zyflo (zileuton) [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3653":"<p><b>Title</b> Warfarin / Zileuton</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Zileuton may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of warfarin (eg, elevated PT/INR) if zileuton is initiated/dose increased, and decreased effects if zileuton is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In 24 healthy male volunteers, the R-warfarin AUC increased 22% and the plasma clearance decreased 15% when warfarin (dosed to achieve PT of 14 to 18 seconds) was coadministered with zileuton (600 mg every 6 hours).<sup>1,2</sup> The pharmacokinetics of S-warfarin were not affected by zileuton, but the increased R-warfarin serum concentrations resulted in an increase in PT.<sup>1,2</sup> <br><br>Prescribing information for zileuton states that coadministration of zileuton and warfarin may result in increased warfarin exposure.<sup>2</sup> Monitor PT/INR closely and adjust warfarin doses as needed.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but zileuton may inhibit CYP1A2, an enzyme responsible for the metabolism of R-warfarin.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. <i>Clin Pharmacokinet</i>. 1995;29(suppl 2):67-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8620673\">[PubMed 8620673]</a></p>\n<p>2. Zyflo CR (zileuton) [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; November 2011.</p>\n<p>3. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. <i>Drug Metab Dispos</i>. 2003;31(11):1352-1360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14570767\">[PubMed 14570767]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3654":"<p><b>Title</b> Propranolol / Zileuton</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Zileuton may increase the serum concentration of Propranolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of propranolol if zileuton is initiated/dose increased, or decreased effects if zileuton is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In 16 healthy volunteers, zileuton (600 mg every 6 hours x 5 days) increased the propranolol (80 mg single dose) AUC, maximum serum concentration, and half-life 104%, 52%, and 25%, respectively.<sup>1</sup> Evidence of increased beta blockade (ie, decreased heart rate) accompanied concomitant use of these drugs.<sup>1</sup><br><br>Zileuton prescribing information states that if zileuton is combined with propranolol, patients should be closely monitored for propranolol toxicities and the dose of propranolol should be reduced as necessary.<sup>1</sup><br><br>The mechanism of this interaction is unknown, but zileuton inhibition of CYP1A2, an enzyme involved in propranolol metabolism, may contribute.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zyflo CR (zileuton) [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; November 2011.</p>\n<p>2. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. <i>Drug Metab Dispos</i>. 2003;31(11):1352-1360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14570767\">[PubMed 14570767]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3655":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased neuromuscular blockade when nondepolarizing NMBs are used in concomitant with inhalational anesthetics. A 25-50% reduction in the dose of the NMB may be warranted.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane*, Halothane*, Isoflurane*, Sevoflurane</p>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium*, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The neuromuscular blocking effects of nondepolarizing NMBs may be enhanced by inhalational anesthetics.<sup>1,2,3</sup> Recovery times do not appear to be prolonged. A mechanism for these effects is unclear. Dosage decreases of the NMBs may be needed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Keens SJ, Hunter JM, Snowdon SL, et al, “Potentiation of the Neuromuscular Blockade Produced by Alcuronium With Halothane, Enflurane and Isoflurane,” <i>Br J Anaesth</i>, 1987, 59(8):1011-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3651269\">[PubMed 3651269]</a></p>\n<p>2. Sokoll MD, Gergis SD, Mehta M, et al, “Safety and Efficacy of Atracurium (BW33A) in Surgical Patients Receiving Balanced or Isoflurane Anesthesia,” <i>Anesthesiology</i>, 1983, 58(5):450-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6340561\">[PubMed 6340561]</a></p>\n<p>3. Lee C, Tsai SK, Kwan WF, et al, “Desflurane Potentiates Atracurium in Humans: A Comparative Study With Isoflurane,” <i>J Clin Anesth</i>, 1992, 4(6):448-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1457111\">[PubMed 1457111]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3656":"<p><b>Title</b> Atenolol / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Atenolol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of atenolol (50 mg daily x 5 days) was increased 25% in 19 normal subjects when coadministered with atazanavir (400 mg daily x 11 days).<sup>1</sup> The pharmacokinetics of atazanavir were essentially unaltered. Atazanavir prescribing information states that this potential interaction is unlikely to be of any clinical significance.<sup>1</sup><br><br>The mechanism of this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3657":"<p><b>Title</b> Atazanavir / Efavirenz</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: If atazanavir is combined with efavirenz in the treatment-naive patient, atazanavir should be dosed at 400 mg once daily and must be boosted with either ritonavir (100 mg daily) or cobicistat (150 mg daily). Coadministration of atazanavir with the Atripla combination product (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) is not recommended according to the Atripla prescribing information.</p></li>\n <li><p><b>Indication</b>: The combination of efavirenz and atazanavir should not be used in the treatment-experienced HIV-infected patient.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Atazanavir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Atazanavir (including ritonavir or cobicistat-boosted regimens) is not recommended for use in combination with efavirenz in treatment-experienced patients. In treatment-naive adult patients receiving efavirenz, atazanavir/ritonavir 400 mg/100 mg daily with food or atazanavir/cobicistat 400 mg/150 mg daily is recommended. Monitor patient clinical response to antiviral therapy closely with use of this combination, including monitoring for both inadequate antiviral response and evidence of possible toxicity. Coadministration of atazanavir with the Atripla combination product (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) is not recommended according to the Atripla prescribing information.</p> \n<p><b>Discussion</b> A population study found that average atazanavir minimum serum concentrations (Cmin) were 80% lower with concurrent efavirenz and that among patients treated with efavirenz, the average atazanavir clearance was 54% higher.<sup>1</sup> Similarly, concurrent use of efavirenz (600 mg/day) with atazanavir (400 mg/day) was associated with an average 74% reduction in atazanavir AUC and an average 93% reduction in atazanavir Cmin (n=27).<sup>2</sup> When ritonavir-boosted atazanavir was used (400 mg/100 mg once daily) with efavirenz there was no significant change in atazanavir AUC and an average 42% decrease in atazanavir Cmin.<sup>2</sup><br><br>Efavirenz prescribing information, atazanavir prescribing information, and clinical guidelines recommend that the combination of atazanavir and efavirenz only be used in treatment-naive patients and only with an atazanavir dose of 400 mg daily, and must be boosted with ritonavir (100 mg daily).<sup>2,3,4</sup> Clinical guidelines also endorse boosting with cobicistat 150 mg daily as an alternative to boosting with ritonavir in this scenario.<sup>4</sup><br><br>Atazanavir is a substrate of CYP3A4. Efavirenz is a known inducer of this enzyme, and would thus be expected to increase the metabolism of atazanavir. The addition of ritonavir, and likely cobicistat, to the combination of efavirenz and atazanavir yields atazanavir blood concentrations similar to those produced by administration of atazanavir 400 mg without efavirenz via ritonavir-mediated inhibition of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dailly E, Tribut O, Tattevin P, et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. <i>Eur J Clin Pharmacol</i>. 2006;62(7):523-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16763827\">[PubMed 16763827]</a></p>\n<p>2. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2015.</p>\n<p>3. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2015.</p>\n<p>4. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Published April 2015. Accessed April 24, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3658":"<p><b>Title</b> Atazanavir / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Atazanavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Antacids should be administered 1 hour before or 2 hours after atazanavir in order to minimize the risk of a clinically significant interaction. H2 receptor antagonists and proton pump inhibitors also appear to interact with atazanavir but with a more prolonged interaction due to their longer duration of action.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Coadministration of atazanavir with antacids is expected to result in significant reductions in atazanavir AUC due to reduced absorption.<sup>1</sup> Buffered, oral didanosine administration has been shown to reduce atazanavir AUC by nearly 90% when the products were simultaneously administered, but the atazanavir AUC was not significantly altered when atazanavir was given 1 hour after administration of the buffered didanosine.<sup>1</sup> Atazanavir solubility is greatly reduced with increased pH.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3659":"<p><b>Title</b> Atazanavir / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The magnitude of this interaction may increase with increasing proton pump inhibitor doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Atazanavir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer of atazanavir recommends against concomitant use with proton pump inhibitors (PPI) in HIV treatment-experienced patients due to the potential for reduced efficacy of atazanavir. In treatment-naive patients, proton pump inhibitors may be considered; however, boosted atazanavir therapy should be used, the boosted atazanavir doses should be given either approximately 12 hours after the PPI (atazanavir/ritonavir) or at least 12 hours after the PPI (atazanavir/cobicistat), and the PPI dose should not exceed the equivalent of 20 mg omeprazole. If coadministered, monitor for reduced effectiveness of atazanavir.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole*, Pantoprazole, RABEprazole, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of unboosted atazanavir (400 mg daily) was decreased 94% in normal subjects (n=16) when coadministered with omeprazole (40 mg daily).<sup>1</sup> With ritonavir-boosted therapy (300 mg atazanavir with ritonavir 100 mg daily), the AUC of atazanavir was decreased 76% in healthy subjects (n=15). In another study of healthy volunteers, a lower omeprazole dose (20 mg daily) reduced the boosted atazanavir (atazanavir/ritonavir 300/100 mg) AUC and minimum concentration by 42% and 46%, respectively.<sup>2</sup> In a study of 10 healthy volunteers, coadministration of atazanavir 400mg with lansoprazole 60mg resulted in a 94% decrease in atazanavir AUC(0-24h), similar to results seen at the 40 mg daily omeprazole dose.<sup>3</sup> <br><br>Atazanavir solubility is greatly reduced with increased pH, and drug absorption is thereby reduced. The ingestion of 8 ounces of cola drink (an attempt to decrease gastric pH and therefore increase atazanavir solubility) yielded little benefit.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, November 2009.</p>\n<p>2. Zhu L, Persson A, Mahnke L, et al, “Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2010 May 10. Epub ahead of print. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20457590\">[PubMed 20457590]</a></p>\n<p>3. Tomilo DL, Smith PF, Ogundele AB, et al, “Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers,” <i>Pharmacotherapy</i>, 2006, 26:341-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16503713\">[PubMed 16503713]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3661":"<p><b>Title</b> Cocaine (Topical) / Modafinil</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Modafinil does not appear to alter the pharmacodynamic effect(s) of Cocaine (Topical). <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Single intravenous doses of cocaine (30 mg) given to 6 normal subjects after 4-day regimens of modafinil (200-400 mg/day) was not associated with alterations in blood pressure, pulse, temperature, or electrocardiogram measures.<sup>1</sup> Neither cocaine-induced euphoria or craving were intensified by modafinil. Modafinil is a potential treatment option for cocaine dependence.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dackis CA, Lynch KG, Yu E, et al, “Modafinil and Cocaine: A Double-Blind, Placebo-Controlled Drug Interaction Study,” <i>Drug Alcohol Depend</i>, 2003, 70(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12681523\">[PubMed 12681523]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3663":"<p><b>Title</b> Ketoprofen / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Ketoprofen. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased ketoprofen effects/toxicity when coadministered with probenecid. Reduced ketoprofen doses may be required.</p> \n<p><b>Discussion</b> The total clearance of ketoprofen (50 mg every 6 hours) was reduced 67% and the maximum serum concentration increased by 67% when administered with probenecid (500 mg every 6 hours) in 6 healthy volunteers.<sup>1</sup> Similarly, the AUC of both R- and S- ketoprofen were increased by an average of 2- and 2.5-fold, respectively, in a study of 5 cholecystectomy patients who received ketoprofen (50 mg) with probenecid (1,000 mg).<sup>2</sup> <br><br>The prescribing information for probenecid states that ketoprofen concentrations may be increased when combined with probenecid.<sup>3</sup> Close monitoring and a ketoprofen dose reduction may be warranted.<sup>3</sup><br><br>The mechanism of this proposed interaction has not been fully investigated, but probenecid has been proposed to inhibit the renal secretion and/or glucuronidation of ketoprofen.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Upton RA, Williams RL, Buskin JN, Jones RM. Effects of probenecid on ketoprofen kinetics. <i>Clin Pharmacol Ther</i>. 1982;31(6):705-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075118\">[PubMed 7075118]</a></p>\n<p>2. Foster RT, Jamali F, Russell AS. Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid. <i>Eur J Clin Pharmacol</i>. 1989;37(6):589-594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2612555\">[PubMed 2612555]</a></p>\n<p>3. Probenecid [prescribing information]. Philadelphia, PA: Lannett Company Inc; October 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3664":"<p><b>Title</b> Pyridostigmine / Methocarbamol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methocarbamol may diminish the therapeutic effect of Pyridostigmine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced effects of pyridostigmine if coadministered with methocarbamol. An alternative to methocarbamol might be considered.</p> \n<p><b>Discussion</b> Case report. A pyridistigmine-controlled myasthenia gravis patient experienced weakness following the initiation of methocarbamol (1 g 4-5 times/day) on two separate occasions.<sup>1</sup> Methocarbamol discontinuation was accompanied by a return to normal. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Podrizki A, “Methocarbamol and Myasthenia Gravis,” <i>JAMA</i>, 1968, 205(13):938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5695627\">[PubMed 5695627]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3665":"<p><b>Title</b> Digoxin / Hawthorn</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Hawthorn does not appear to affect serum concentration of Digoxin. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concomitant therapy with hawthorn (450 mg twice daily of Crataegus special extract WS 1442 [hawthorn leaves and flowers; Dr. Willmar Schwabe Pharmaceuticals]) did not alter the AUC of digoxin (0.25 mg/day) in 8 normal subjects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tankanow R, Tamer HR, Streetman DS, et al, “Interaction Study Between Digoxin and a Preparation of Hawthorn (Crataegus oxyacantha),” <i>J Clin Pharmacol</i>, 2003, 43(6):637-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12817526\">[PubMed 12817526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3666":"<p><b>Title</b> Antiemetics (5HT3 Antagonists) / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Aprepitant does not appear to affect serum concentration of Antiemetics (5HT3 Antagonists). <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antiemetics (5HT3 Antagonists) Interacting Members</b> Alosetron, Dolasetron, Granisetron*, Ondansetron*, Palonosetron, Ramosetron, Tropisetron</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Aprepitant administration did not appreciably affect the pharmacokinetic profiles of either intravenous ondansetron or oral granisetron in normal subjects.<sup>1</sup> The drugs were administered in fashions similar to clinically employed regimens for the prevention of chemotherapy-induced nausea and vomiting. No data are available for dolasetron. However, no interactions are presently expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blum RA, Majumdar A, McCrea, et al, “Effects of Aprepitant on the Pharmacokinetics of Ondansetron and Granisetron in Healthy Subjects,” <i>Clin Ther</i>, 2003, 25(5):1407-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12867217\">[PubMed 12867217]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3668":"<p><b>Title</b> Flucytosine / Cytarabine (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Employ caution in the concomitant use of cytarabine and flucytosine. Monitor for decreased effects of flucytosine.</p> \n<p><b>Discussion</b> The serum concentrations of flucytosine was decreased by 35% in one patient, and to undetectable levels in another, following the initiation of cytarabine therapy.<sup>1,2</sup> The decreased levels in the former patient were still considered therapeutically effective.<sup>2</sup> In vitro data from the latter patient demonstrated an abolishment of the effect of flucytosine against cryptococcus in the presence of cytarabine.<sup>1</sup> Other in vitro data fails to support this observation.<sup>2</sup> The mechanism for the observations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wingfield HJ, “Absence of Fungistatic Antagonism Between Flucytosine and Cytarabine in vitro and in vivo,” <i>J Antimicrob Chemother</i>, 1987, 20(4):523-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3316150\">[PubMed 3316150]</a></p>\n<p>2. Holt RJ, “Clinical Problems With 5-fluorocytosine,” <i>Mykosen</i>, 1978, 21(11):363-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=740016\">[PubMed 740016]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3669":"<p><b>Title</b> Flucytosine / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of flucytosine toxicity, and monitor for signs of renal dysfunction following amphotericin B administration as this may increase the risk for flucytosine toxicity.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> Since flucytosine elimination is largely dependent on glomerular filtration,<sup>1</sup> and amphotericin B use can be complicated by renal dysfunction, the potential for a clinically significant interaction exists. Both amphotericin B<sup>2</sup> labeling and flucytosine reviews<sup>1</sup> describe this potential interaction. Of note, an additional mechanism for this possible interaction has been proposed, suggesting that amphotericin B may increase the cellular uptake of flucytosine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vermes A, Guchelaar HJ, Dankert J, “Flucytosine: A Review of Its Pharmacology, Clinical Indications, Pharmacokinetics, Toxicity and Drug Interactions,” <i>J Antimicrob Chemother</i>, 2000, 46(2):171-9. [PMID 10933638]</p>\n<p>2. Prescribing information. AmBisome (amphotericin B). San Dimas, CA: Gilead Sciences, Inc., October 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3670":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / CYP1A2 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Strong) Interacting Members</b> FluvoxaMINE</p>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3671":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / CYP1A2 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Moderate) Interacting Members</b> Ciprofloxacin (Systemic), Deferasirox, Methoxsalen (Systemic), Mexiletine, Stiripentol, Thiabendazole, Vemurafenib</p>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3672":"<p><b>Title</b> CYP2A6 Substrates (High risk with Inhibitors) / CYP2A6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2A6 Inhibitors (Moderate) Interacting Members</b> Amiodarone, Desipramine, Isoniazid, Ketoconazole (Systemic)</p>\n <p><b>CYP2A6 Substrates (High risk with Inhibitors) Interacting Members</b> Dexmedetomidine, Tegafur</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3673":"<p><b>Title</b> CYP2A6 Substrates (High risk with Inhibitors) / CYP2A6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2A6 Inhibitors (Strong) Interacting Members</b> Letrozole, Methoxsalen (Systemic), Tranylcypromine</p>\n <p><b>CYP2A6 Substrates (High risk with Inhibitors) Interacting Members</b> Dexmedetomidine, Tegafur</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3676":"<p><b>Title</b> CYP2C19 Substrates (High risk with Inhibitors) / CYP2C19 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C19 Inhibitors (Moderate) Interacting Members</b> FLUoxetine, FluvoxaMINE, Moclobemide, Stiripentol, Voriconazole</p>\n <p><b>CYP2C19 Substrates (High risk with Inhibitors) Interacting Members</b> Carisoprodol, Cilostazol, Citalopram, CloBAZam, ClomiPRAMINE, Clopidogrel, DiazePAM, Dosulepin, Dydrogesterone, Escitalopram, Etizolam, Fosphenytoin, Imipramine, Methsuximide, Moclobemide, Nilutamide, PHENobarbital, Phenytoin, Stiripentol, Trimipramine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3677":"<p><b>Title</b> CYP2C19 Substrates (High risk with Inhibitors) / CYP2C19 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C19 Inhibitors (Strong) Interacting Members</b> Fluconazole</p>\n <p><b>CYP2C19 Substrates (High risk with Inhibitors) Interacting Members</b> Carisoprodol, Cilostazol, Citalopram, CloBAZam, ClomiPRAMINE, Clopidogrel, DiazePAM, Dosulepin, Dydrogesterone, Escitalopram, Etizolam, Fosphenytoin, Imipramine, Methsuximide, Moclobemide, Nilutamide, PHENobarbital, Phenytoin, Stiripentol, Trimipramine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3678":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol<br><b>Exception</b> Tamoxifen</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3679":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tetrabenazine, Thioridazine, Timolol (Systemic), Tolterodine, Trimipramine, Venlafaxine, Vortioxetine, Zuclopenthixol<br><b>Exceptions</b> Ajmaline, Dapoxetine, Indoramin, Tamoxifen, Timolol (Ophthalmic), Tropisetron</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3680":"<p><b>Title</b> CYP2E1 Substrates (High risk with Inhibitors) / CYP2E1 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2E1 Inhibitors (Moderate) Interacting Members</b> Chlormethiazole, Isoniazid</p>\n <p><b>CYP2E1 Substrates (High risk with Inhibitors) Interacting Members</b> Dacarbazine, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3681":"<p><b>Title</b> CYP2E1 Substrates (High risk with Inhibitors) / CYP2E1 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2E1 Inhibitors (Strong) may decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2E1 Inhibitors (Strong) Interacting Members</b> Disulfiram</p>\n <p><b>CYP2E1 Substrates (High risk with Inhibitors) Interacting Members</b> Dacarbazine, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3682":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Zopiclone<br><b>Exceptions</b> Alitretinoin (Systemic), Praziquantel, Trabectedin, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3683":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to minimize the risk for toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable labeling. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased. Note that drugs marked as an “Exception” herein are either discussed individually or are otherwise not expected to participate in the interaction - please search for the individual drug in question for more information.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, ALPRAZolam, Amiodarone, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Zopiclone<br><b>Exceptions</b> Alitretinoin (Systemic), AmLODIPine, Benzhydrocodone, Buprenorphine, Gefitinib, HYDROcodone, Praziquantel, Telithromycin, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> The strong CYP3A4 inhibitors in this monograph are expected to reduce the metabolism of the CYP3A4 substrates. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via in vitro studies) is likely to be achieved during the course of standard dosing of the drug; or b) in vivo pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup><br><br>Drugs marked as an “Exception” above are either discussed individually or are otherwise not expected to participate in the interaction - please search for the individual drug in question for more information.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. <i>J Clin Pharmacol</i>. 2003;43(5):443-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3684":"<p><b>Title</b> Memantine / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of memantine if coadministered with a carbonic anhydrase inhibitor.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, the median memantine (10 mg daily) clearance decreased approximately 80% and the median memantine AUC increased approximately 19% when combined with sodium bicarbonate (to achieve a urinary pH of 8) compared with the combination of memantine and ammonium chloride (to achieve a urinary pH of 5).<sup>1</sup> The manufacturer reports that memantine clearance was reduced by approximately 80% when the urinary pH was raised to 8.<sup>2,3</sup> <br><br>Coadministration of memantine with drugs that can increase urinary pH (eg, carbonic anhydrase inhibitors) may result in elevated serum concentrations of memantine and increased risk of adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy U, Gleiter CH. Influence of urine pH and urinary flow on the renal excretion of memantine. <i>Br J Clin Pharmacol</i>. 1998;46(6):541-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9862242\">[PubMed 9862242]</a></p>\n<p>2. Namenda (memantine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; October 2013.</p>\n<p>3. Namzaric (memantine/donepezil) [prescribing information]. Clonshaug, Dublin, Ireland: Forest Pharmaceuticals Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3688":"<p><b>Title</b> Anthracyclines / Trastuzumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Trastuzumab may enhance the cardiotoxic effect of Anthracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab. Frequent monitoring for signs and symptoms of cardiac dysfunction in patients receiving anthracyclines plus trastuzumab must be conducted. The incidence of heart failure is significantly higher with combination therapy than with either agent alone. If evidence of heart failure develops, consideration should be given to discontinuing trastuzumab therapy.</p>\n<div>\n <p><b>Anthracyclines Interacting Members</b> DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, IDArubicin</p>\n</div> \n<p><b>Discussion</b> Phase II trials provide evidence that the incidence of cardiotoxicity associated with coadministration of trastuzumab, cyclophosphamide, and an anthracycline (28%) is greater than either trastuzumab alone (7%) or the combination of a cyclophosphamide and an anthracycline (7%).<sup>1</sup> The mechanism of trastuzumab cardiotoxicity is unclear; however, it appears to be different from, and synergistic with, anthracyclines. HER2 proteins (receptors) are not only expressed in some breast carcinomas, but also in cardiac tissue.<sup>2,3</sup> The implications of blocking HER2 receptors in the heart are unclear. A pharmacokinetic study revealed no affects of trastuzumab on epirubicin AUC.<sup>4</sup> Trastuzumab-related cardiotoxicity, unlike that induced by anthracyclines, usually responds to therapy discontinuation and/or standard heart failure treatments.<sup>5</sup><br><br>The trastuzumab prescribing information recommends that patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab based on the long wash-out period for trastuzumab.<sup>1</sup> It is reported that approximately 97% of trastuzumab is removed by 7 months after cessation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Herceptin</i> (trastuzumab) [prescribing information]. South San Francisco, CA: Genetech, Inc.; April 2015.</p>\n<p>2. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. <i>Science</i>. 1992;256(5060):1205-1210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1350381\">[PubMed 1350381]</a></p>\n<p>3. Rohrbach S, Yan X, Weinberg EO, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. <i>Circulation</i>. 1999;100(4):407-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10421602\">[PubMed 10421602]</a></p>\n<p>4. Lunardi G, Vannozzi MO, Bighin C, et al. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. <i>Ann Oncol</i>. 2003;14(8):1222-1226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12881383\">[PubMed 12881383]</a></p>\n<p>5. Keefe DL. Trastuzumab-associated cardiotoxicity. <i>Cancer</i>. 2002;95(7):1592-1600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12237930\">[PubMed 12237930]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3691":"<p><b>Title</b> Digoxin / Ginkgo Biloba</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Ginkgo Biloba does not appear to affect serum concentration of Digoxin. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of digoxin (0.5 mg single oral dose) was essentially unchanged in 8 normal subjects when administered following a one-week course of ginkgo biloba (80 mg 3 times/day).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mauro VF, Mauro LS, Kleshinski JF, et al, “Impact of Ginkgo Biloba on the Pharmacokinetics of Digoxin,” <i>Am J Therapeutics</i>, 2003, 10(4):247-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12845387\">[PubMed 12845387]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3695":"<p><b>Title</b> Alcohol (Ethyl) / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased CNS depression when alcohol is coadministered with other CNS depressants. Caution patients of these effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Ethanol is a CNS depressant. Additive effects (ie, increased CNS depression) can be anticipated when coadministered with other drugs that possess CNS-depressing properties.<sup>1</sup> Blood alcohol levels within the legal driving limits may likely be very unsafe in the presence of other CNS depressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Worthley LI, “Clinical Toxicology: Part I. Diagnosis and Management of Common Drug Overdosage,” <i>Crit Care Resusc</i>, 2002, 4(3):192-215. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573429\">[PubMed 16573429]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3696":"<p><b>Title</b> Alcohol (Ethyl) / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Coadministration of disulfiram and alcohol should be avoided (such is the therapeutic purpose of disulfiram). Alcohol may be contained in beverages and pharmaceutical products (eg, elixirs). The application of topical products containing alcohol might also present problems.</p> \n<p><b>Discussion</b> The coadministration of alcohol and disulfiram results in an array of symptoms including throbbing in the head and neck, flushing, sweating, nausea, vomiting, chest pain, and breathing difficulties. These effects were first described in 1937 when rubber industry workers handling tetramethylthiuram disulphide.<sup>1</sup> The syndrome was later characterized with the disulfiram.<sup>2</sup> Disulfiram inhibits aldehyde dehydrogenase, the enzyme responsible for converting acetaldehyde (the first metabolite of alcohol) into, eventually, water and carbon dioxide. Acetaldehyde accumulation results in the toxic reactions observed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Williams EE. Effects of alcohol on workers with carbon disulfide. <i>JAMA</i>. 1937;109:1472.</p>\n<p>2. Hald J, Jacobsen E, Larsen V. The sensitizing effects of tetramethylthiuramdisulfide (Antabuse) to ethylalcohol. <i>Acta Pharmacol</i>. 1948;4:285-296.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3697":"<p><b>Title</b> Alcohol (Ethyl) / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for flushing, tachycardia, and disulfiram-like reaction during coadministration of alcohol and griseofulvin. Alcohol may be contained in beverages and pharmaceutical products (eg, elixirs).</p> \n<p><b>Discussion</b> Coadministration of griseofulvin and alcohol has resulted in a single case of disulfiram-like reaction.<sup>1</sup> Other cases of flushing and tachycardia associated with coadministration of these products have been reported.<sup>2</sup> The mechanism is unclear. Griseofulvin may inhibit aldehyde dehydrogenase, like disulfiram, and thus reduce the metabolism of acetaldehyde (the metabolite of alcohol).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fett DL and Vukov LF, “ An Unusual Case of Severe Griseofulvin-Alcohol Interaction,” <i>Ann Emerg Med</i>, 1994, 24:95-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8010556\">[PubMed 8010556]</a></p>\n<p>2. Fulvicin P/G [package insert]. Kenilworth, NJ: Schering Corporation, 1996.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3699":"<p><b>Title</b> Alcohol (Ethyl) / Procarbazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Procarbazine may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Patients treated with procarbazine should avoid concomitant alcohol use.</p> \n<p><b>Discussion</b> The prescribing information for procarbazine warns that patients should not consume alcohol while taking procarbazine as a disulfiram-like reaction may occur.<sup>1</sup> Case reports of patients receiving procarbazine describe facial flushing after consuming alcoholic beverages.<sup>2,3</sup> <br><br>Procarbazine is also a known monoamine oxidase inhibitor (MAOI). The prescribing information for other MAOIs (isocarboxazid, phenelzine, and tranylcypromine) list alcohol use as a contraindication,<sup>4,5,6</sup> and product labeling for both transdermal selegiline and moclobemide (available only in Canada) recommend avoidance of alcohol consumption.<sup>7,8</sup> <br><br>In addition to the risk of a disulfiram-like reaction, alcohol is a CNS depressant, and may potentiate the CNS side effects of MAOIs. Furthermore, certain alcoholic beverages (beer, red wine, etc.) may provide additional sources of tyramine, thus increasing a patient’s risk for a hypertensive crisis. <sup>9</sup> Patients taking procarbazine should avoid alcohol consumption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Matulane</i> (procarbazine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; February 2004.</p>\n<p>2. Mathe G, Schweisguth O, Schneider M, et al. Methyl-hydrazine in the treatment of Hodgkin's disease and various forms of haematosarcoma and leukaemia. <i>Lancet</i>. 1963;2(7317):1077-1080. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14063416\">[PubMed 14063416]</a></p>\n<p>3. Todd ID. Natulan in the management of late Hodgkin's disease, other lymphoreticular neoplasms, and malignant melanoma. <i>Br Med J</i>. 1965;1(5435):628-631. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14245179\">[PubMed 14245179]</a></p>\n<p>4. <i>Marplan</i> (isocarboxazid) [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; June 2007.</p>\n<p>5. <i>Nardil</i> (phenelzine) [prescribing information]. New York, NY: Pfizer; May 2007.</p>\n<p>6. <i>Parnate</i> (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.</p>\n<p>7. <i>Apo-Moclobemide</i> (moclobemide) [product monograph]. Weston, Ontario, Canada: Apotex Inc; March 2009.</p>\n<p>8. <i>Emsam</i> (selegiline) [prescribing information]. Morgantown WV: Somerset Pharmaceuticals Inc; January 2010.</p>\n<p>9. Shulman KI, Tailor SA, Walker SE, Gardner DM. Tap (draft) beer and monoamine oxidase inhibitor dietary restrictions. <i>Can J Psychiatry</i>. 1997;42(3):310-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9114949\">[PubMed 9114949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}